var title_f22_34_23072="Neonatal resuscitation algorithm";
var content_f22_34_23072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Neonatal resuscitation algorithm: 2010 guidelines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 638px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CPAP: continuous positive airway pressure; HR: heart rate; IV: intravenous; min: minute; PPV: positive pressure ventilation; SpO",
"     <sub>",
"      2",
"     </sub>",
"     : oxygen saturation measured by pulse oximetry.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission. Neonatal Resuscitation: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. &copy; 2010 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23072=[""].join("\n");
var outline_f22_34_23072=null;
var title_f22_34_23073="Dilated sleeve gastrectomy";
var content_f22_34_23073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Dilated sleeve gastrectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrow shows hiatal hernia and a dilated sleeve gastrectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23073=[""].join("\n");
var outline_f22_34_23073=null;
var title_f22_34_23074="Podofilox: Drug information";
var content_f22_34_23074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Podofilox: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/28/35267?source=see_link\">",
"    see \"Podofilox: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Condylox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Condyline&trade;;",
"     </li>",
"     <li>",
"      Wartec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Keratolytic Agent;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Genital warts:",
"     </b>",
"     Topical: Apply twice daily (morning and evening) for 3 consecutive days, then withhold use for 4 consecutive days; this cycle may be repeated up to 4 times until there is no visible wart tissue",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Condylox&reg;: 0.5% (3.5 g) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 0.5% (3.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Condylox&reg;: 0.5% (3.5 mL) [contains ethanol 95%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Topical solution",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of external genital warts",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10893724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13375006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies with topical administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13375007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F210941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Condylox External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (3.5 g): $434.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Condylox External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (3.5 mL): $202.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Podofilox External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (3.5 mL): $99.48",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F210942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Condyline (BG, CH, DK, FI, FR, GB, HN, IE, IN, IT, NL, NO, PT, RU, SE);",
"     </li>",
"     <li>",
"      Condyline Liquid (NZ);",
"     </li>",
"     <li>",
"      Condyline Paint (AU);",
"     </li>",
"     <li>",
"      Condylox (AT, CL, DE, IL);",
"     </li>",
"     <li>",
"      Podofilox (GR);",
"     </li>",
"     <li>",
"      Podox (CO);",
"     </li>",
"     <li>",
"      Podoxin (AR, UY);",
"     </li>",
"     <li>",
"      Warix (CH);",
"     </li>",
"     <li>",
"      Wartec (BE, DE, DK, EE, FI, GR, HK, NO, PE, PK, PL, SE, SG, ZA);",
"     </li>",
"     <li>",
"      Warticon (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/34/23074/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10218 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23074=[""].join("\n");
var outline_f22_34_23074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210948\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210946\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210947\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210938\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210929\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210939\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10893724\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299893\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222378\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210934\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13375006\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13375007\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210941\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210942\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10218|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/28/35267?source=related_link\">",
"      Podofilox: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_34_23075="Patient information: Hip replacement (The Basics)";
var content_f22_34_23075=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15808\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/1/43026\">",
"         Hip anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/43/17073\">",
"          Hip replacement prosthesis",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/33/14867\">",
"         Patient information: Hip fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/25/43409\">",
"         Patient information: Hip pain in older people (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/3/43058\">",
"         Patient information: Osteoarthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/46/24289\">",
"         Patient information: Hip pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/21/18769\">",
"         Patient information: Joint infection (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/29/21975\">",
"         Patient information: Osteoarthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/44/24264\">",
"         Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/30/21987\">",
"         Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hip replacement (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hip-replacement-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H23883878\">",
"      <span class=\"h1\">",
"       What is hip replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hip replacement is a type of surgery in which a doctor replaces a person&rsquo;s hip joint with a man-made hip joint.",
"     </p>",
"     <p>",
"      The hip joint is a type of joint called a &ldquo;ball and socket joint.&rdquo; It&rsquo;s called that because the top of the thigh bone is ball-shaped and fits into part of the pelvic bones (",
"      <a class=\"graphic graphic_figure graphicRef70663 \" href=\"UTD.htm?42/1/43026\">",
"       figure 1",
"      </a>",
"      ). Normally, a person&rsquo;s hip joint can move smoothly in many directions.",
"     </p>",
"     <p>",
"      When people have problems with their hip joint, the hip can be painful, stiff, and have trouble moving normally. Different conditions can cause problems with the hip joint, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Osteoarthritis &ndash; This is the most common type of arthritis and often comes with age.",
"       </li>",
"       <li>",
"        Other types of arthritis, such as rheumatoid arthritis",
"       </li>",
"       <li>",
"        Hip problems that people are born with or get during childhood",
"       </li>",
"       <li>",
"        Hip injuries",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Hip replacement is a treatment that can reduce hip pain and improve the way the hip moves.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23883885\">",
"      <span class=\"h1\">",
"       When are hip joint problems treated with hip replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hip joint problems from arthritis can be treated with hip replacement right away. But doctors sometimes suggest trying other treatments first, such as weight loss, medicines, physical therapy, or devices such as canes or walkers. If these treatments do not help enough, then doctors might suggest hip replacement.",
"     </p>",
"     <p>",
"      One reason doctors suggest trying other treatments first is that a replacement hip joint can wear out over time. Hip replacements usually last at least 10 to 15 years, and some last longer. The number of years a replacement hip joint lasts depends on different factors, such as how active the person is.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23883892\">",
"      <span class=\"h1\">",
"       What happens during hip replacement surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hip replacement surgery takes place in an operating room in a hospital. A doctor will give you medicines to make you sleep and to numb your body. Then your doctor will make a cut on your outer hip and thigh. He or she will replace your hip joint with a man-made hip joint, called a prosthesis. A prosthesis can be made out of plastic, metal, or ceramic (",
"      <a class=\"graphic graphic_figure graphicRef65030 \" href=\"UTD.htm?16/43/17073\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23883899\">",
"      <span class=\"h1\">",
"       What happens after surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After surgery, most people stay in the hospital for 2 to 4 days. While you are in the hospital, you will get:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to treat your pain",
"       </li>",
"       <li>",
"        Antibiotic medicines to prevent infections",
"       </li>",
"       <li>",
"        Medicines to prevent blood clots in the legs",
"       </li>",
"       <li>",
"        Special boots or stockings to prevent blood clots in the legs",
"       </li>",
"       <li>",
"        Physical therapy &ndash; Most people are able to stand and walk (with help) within 1 day after surgery. The physical therapist will teach you exercises to make the muscles around your hip stronger. He or she will work with you on bending, walking, and climbing stairs so that you can move normally.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23883906\">",
"      <span class=\"h1\">",
"       Where do I go after I leave the hospital?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people go home. But some people stay in a nursing home or rehabilitation facility for a short time in order to get stronger before going home. Wherever you go, you will need to do your exercises and have physical therapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23883913\">",
"      <span class=\"h1\">",
"       When will I be able to do my usual activities again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people can do their usual activities again within 3 to 6 months. Your doctor or nurse will tell you if there are any activities that you should avoid.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23883920\">",
"      <span class=\"h1\">",
"       What problems can people have from hip replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can have different problems from hip replacement, but serious problems are uncommon. Problems from hip replacement can happen:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        During hip replacement &ndash; For example, a bone can break, or nerves or blood vessels can be damaged.",
"       </li>",
"       <li>",
"        Right after hip replacement &ndash; People can get an infection or blood clots in the legs. Also, the thigh bone or prosthesis can pop out of place.",
"       </li>",
"       <li>",
"        Years after hip replacement &ndash; The hip joint can become loose and pop out of place, become stiff, or wear out.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23883927\">",
"      <span class=\"h1\">",
"       How do I know if hip replacement is right for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help you decide if hip replacement is right for you, talk with your doctor or nurse. You can ask him or her:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of hip replacement?",
"       </li>",
"       <li>",
"        What are the downsides to hip replacement?",
"       </li>",
"       <li>",
"        Are there other options besides hip replacement?",
"       </li>",
"       <li>",
"        What happens if I do not have hip replacement?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23883934\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       Patient information: Osteoarthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=see_link\">",
"       Patient information: Hip pain in older people (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/33/14867?source=see_link\">",
"       Patient information: Hip fracture (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"       Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"       Patient information: Osteoarthritis treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/46/24289?source=see_link\">",
"       Patient information: Hip pain (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"       Patient information: Joint infection (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link\">",
"       Total hip arthroplasty",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link\">",
"       Complications of total hip arthroplasty",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"       Surgical therapy of osteoarthritis",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=see_link\">",
"       Total joint replacement for severe rheumatoid arthritis",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"       Treatment of prosthetic joint infections",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/34/23075?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15808 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23075=[""].join("\n");
var outline_f22_34_23075=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883878\">",
"      What is hip replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883885\">",
"      When are hip joint problems treated with hip replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883892\">",
"      What happens during hip replacement surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883899\">",
"      What happens after surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883906\">",
"      Where do I go after I leave the hospital?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883913\">",
"      When will I be able to do my usual activities again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883920\">",
"      What problems can people have from hip replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883927\">",
"      How do I know if hip replacement is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23883934\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15808\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/1/43026\">",
"      Hip anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/43/17073\">",
"       Hip replacement prosthesis",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=related_link\">",
"      Complications of total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/33/14867?source=related_link\">",
"      Patient information: Hip fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/46/24289?source=related_link\">",
"      Patient information: Hip pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=related_link\">",
"      Patient information: Hip pain in older people (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=related_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=related_link\">",
"      Total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_34_23076="Pathophysiology of heart failure: Left ventricular pressure-volume relationships";
var content_f22_34_23076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23076/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23076/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23076/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23076/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23076/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23076/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/34/23076/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure may be due to either systolic or diastolic dysfunction of the left ventricle. While both are characterized by elevated left ventricular filling pressures, the underlying hemodynamic processes differ considerably. These differences can be best understood when described in terms of the left ventricular pressure-volume relationship. Understanding these principles has practical implications for the treatment of patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL LEFT VENTRICULAR PRESSURE-VOLUME RELATIONSHIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a pump, the ventricle generates pressure (to eject blood) and displaces a volume of blood. The normal relationship between left ventricular (LV) pressure generation and ejection can be expressed as a plot of LV pressure versus LV volume (",
"    <a class=\"graphic graphic_figure graphicRef73169 \" href=\"UTD.htm?25/10/25772\">",
"     figure 1",
"    </a>",
"    ). At end&ndash;diastole, the fibers have a particular stretch or length, which is determined by the resting force, myocardial compliance, and the degree of filling from the left atrium. This distending force is the preload of the muscle.",
"   </p>",
"   <p>",
"    After depolarization, the ventricle generates pressure isovolumically (without any change in volume), which leads to the opening of the aortic valve and the ejection of blood. Up to this point, the course of systolic pressure is related to the force created by the myocardium. The magnitude of this force is a function of both chamber pressure and volume. During ejection, the myocardium must also sustain a particular force, which is a function of the resistance and capacitance of the circulatory vasculature and is called the afterload.",
"   </p>",
"   <p>",
"    The volume of ejected blood represents the forward effective stroke volume of systolic contraction. At end&ndash;ejection, the aortic valve closes followed by isovolumic relaxation, as left ventricular pressure falls while volume remains constant. When pressure falls sufficiently, the mitral valve opens and left ventricular diastolic filling begins (",
"    <a class=\"graphic graphic_figure graphicRef73169 \" href=\"UTD.htm?25/10/25772\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thus, the three major determinants of the left ventricular forward stroke",
"    <span class=\"nowrap\">",
"     volume/performance",
"    </span>",
"    are the preload (venous return and end&ndash;diastolic volume), myocardial contractility (the force generated at any given end&ndash;diastolic volume) and the afterload (aortic impedance and wall stress) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23076/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Landmark studies by Frank and Starling established the relationship between ventricular end&ndash;diastolic volume (preload) and ventricular performance (stroke volume, cardiac output,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stroke work). Subsequent studies have shown that the isovolumetric force at any given contractile state is a function of the degree of end&ndash;diastolic fiber stretch. These mechanical characteristics of contraction are based upon the ultrastructure of cardiac muscle. Increasing sarcomere length up to a point increases the area of overlap between actin filaments and portions of the myosin filaments containing force&ndash;generating cross&ndash;bridges, thereby allowing increased tension development (",
"    <a class=\"graphic graphic_figure graphicRef63547 \" href=\"UTD.htm?43/45/44765\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23076/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, there is an augmentation of developed force as end&ndash;diastolic volume and fiber length increase. The left ventricle normally functions on the ascending limb of this force&ndash;length relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contractility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stroke volume at any given fiber length is also a function of contractility, as variations in contractility create nonparallel shifts in the developed force&ndash;length relation. Each myocardial cell is capable of varying the amount of tension generated during contraction. This tension is a function of the amount of calcium bound to a regulatory site on the troponin complex of the myofilaments. The amount of calcium available is in turn a function of intracellular calcium delivery.",
"   </p>",
"   <p>",
"    Drug therapy can alter the developed force-length relation. For example, the administration of norepinephrine stimulates cardiac adrenergic receptors which increase myocardial cell cAMP levels, thereby raising the intracellular calcium concentration and contractility. As a result, the ventricle is able to develop a greater force from any given fiber length. Administration of a beta-blocker, on the other hand, attenuates the slope of the force&ndash;length relation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Afterload",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third element determining ventricular performance is the impedance during ejection, the afterload. The afterload on the shortening fibers is defined as the force per unit area acting in the direction in which these fibers are arranged in the ventricular wall. This constitutes the wall stress and can be estimated by applying Laplace's Law [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23076/abstract/3\">",
"     3",
"    </a>",
"    ]. Changes in ventricular volume and wall thickness as well as aortic pressure or aortic impedance determine the afterload. As an example, elevations in systolic pressure act to reduce the ejected fraction of stroke volume from any particular diastolic volume.",
"   </p>",
"   <p>",
"    This relationship can be viewed as a type of feedback control of myocardial contraction. A primary increment in stroke volume, for example, leads to an increase in aortic impedance. As a result of this rise in afterload, subsequent contractions have an attenuated stroke volume. If, on the other hand, an increment in aortic impedance is the initial event, the accompanying reduction in stroke volume should lead to a greater end&ndash;ejection and end&ndash;diastolic chamber volume. The ensuing prolongation of fiber length should restore stroke volume to the baseline level.",
"   </p>",
"   <p>",
"    Stroke volume is only minimally altered by changes in afterload in the normal heart. In comparison, the failing heart is progressively more afterload-dependent and small changes in afterload can produce large changes in stroke volume (",
"    <a class=\"graphic graphic_figure graphicRef55742 \" href=\"UTD.htm?38/50/39725\">",
"     figure 3",
"    </a>",
"    ). Reducing afterload in patients with heart failure, via the administration of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or direct vasodilators (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ), has the dual advantage of increasing cardiac output and, over the long-term, slowing the rate of loss of myocardial function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRESSURE-VOLUME RELATIONSHIPS IN HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systolic and diastolic dysfunction of the left ventricle can be understood by analysis of the relationships between left ventricular developed pressure and volume [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23076/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term systolic dysfunction refers to a decrease in myocardial contractility. As a result, the slope of the relationship between initial length and developed force is reduced (as in the &szlig; beta-blocker example above) and the curve is shifted to the right. This shift is associated with a reduction in stroke volume, and consequently, cardiac output. The fall in cardiac output leads to increased sympathetic activity, which helps to restore cardiac output by increasing both contractility and heart rate. The fall in cardiac output also promotes renal salt and water retention leading to expansion of the blood volume, thereby raising end&ndash;diastolic pressure and volume which, via the Frank-Starling relationship, enhances ventricular performance and tends to restore the stroke volume (",
"    <a class=\"graphic graphic_figure graphicRef58693 \" href=\"UTD.htm?32/56/33677\">",
"     figure 4",
"    </a>",
"    ). Left ventricular hypertrophy is also part of the adaptive response to systolic dysfunction, since it unloads individual muscle fibers and thereby decreases wall stress and afterload.",
"   </p>",
"   <p>",
"    As systolic heart failure progresses, a series of Frank-Starling curves may be seen due to the progressive decline in the maximal cardiac output generated for any given cardiac filling pressure. Flattening of the Frank-Starling curve in advanced disease means that changes in venous return",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular end-diastolic pressure (LVEDP) now fail to increase stroke volume (",
"    <a class=\"graphic graphic_figure graphicRef58693 \" href=\"UTD.htm?32/56/33677\">",
"     figure 4",
"    </a>",
"    ). Two factors may contribute to a plateau in the pressure-volume curve:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The heart may simply have reached its maximum capacity to increase contractility in response to increasing stretch. In vitro studies suggest that this abnormality may result from decreased calcium affinity for and therefore binding to troponin C and from decreased calcium availability within the myocardial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23076/abstract/7\">",
"       7",
"      </a>",
"      ]. These abnormalities may result in part from lengthening of the sarcomeres to a point which exceeds the optimal degree of overlap of thick and thin myofilaments, thereby preventing developed force from increasing in response to increasing load.",
"     </li>",
"     <li>",
"      The Frank-Starling relationship actually applies to left ventricular end-diastolic volume, since it is the stretching of cardiac muscle that is responsible for the enhanced contractility. The more easily measured LVEDP is used clinically since, in relatively normal hearts, pressure and volume vary in parallel. However, cardiac compliance may be reduced with heart disease. As a result, a small increase in volume may produce a large elevation in LVEDP, but no substantial stretching of the cardiac muscle and therefore little change in cardiac output [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23076/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The plateau in the Frank-Starling curve also represents a reduction in the heart's systolic reserve. As a result, the ability of positive inotropic agents to shift this relation to the left and permit greater shortening becomes impaired. In terms of the pressure&ndash;volume plot, the systolic pressure&ndash;volume loop is \"right&ndash;shifted\" with a reduced slope representing the decreased contractility. In contrast, the diastolic pressure&ndash;volume loop is normal initially, although the patient with systolic dysfunction begins at a point farther right on the curve because of the increase in left ventricular volume produced by cardiac dilatation (",
"    <a class=\"graphic graphic_figure graphicRef79423 \" href=\"UTD.htm?22/34/23086\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, decreased compliance due to hypertrophy and fibrosis may eventually produce disturbed diastolic function in many patients with advanced heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23076/abstract/6\">",
"     6",
"    </a>",
"    ]. In this setting, there is also an upward&ndash;shift in the end&ndash;diastolic pressure&ndash;volume relationship as a higher pressure is required to achieve the same volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;With pure diastolic heart failure, left ventricular end&ndash;systolic volume and stroke volume are preserved. There is, however, an abnormal increase in left ventricular diastolic pressure at any given volume. This reflects a decrease in left ventricular diastolic dispensability (or compliance) such that a higher diastolic pressure is required to achieve the same diastolic volume or contractility. In a pressure&ndash;volume plot, diastolic dysfunction would therefore be characterized by a normal systolic pressure volume loop and an \"upward&ndash;shift\" of the diastolic pressure&ndash;volume loop without a change in end-diastolic volume (",
"    <a class=\"graphic graphic_figure graphicRef79423 \" href=\"UTD.htm?22/34/23086\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683611\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal relationship between left ventricular (LV) pressure generation and ejection can be expressed as a plot of LV pressure versus LV volume (Frank Starling curve) (",
"      <a class=\"graphic graphic_figure graphicRef73169 \" href=\"UTD.htm?25/10/25772\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal left ventricular pressure-volume relationship'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major determinants of the left ventricular forward stroke",
"      <span class=\"nowrap\">",
"       volume/performance",
"      </span>",
"      are the preload (venous return and end&ndash;diastolic volume), myocardial contractility (the force generated at any given end&ndash;diastolic volume), and the afterload (aortic impedance and wall stress). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal left ventricular pressure-volume relationship'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With depressed myocardial contractility, the slope of the relationship between myocardial fiber length and developed force is reduced and the Frank Starling curve is shifted to the right (",
"      <a class=\"graphic graphic_figure graphicRef58693 \" href=\"UTD.htm?32/56/33677\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Systolic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With isolated diastolic dysfunction there is a normal systolic pressure volume loop and an \"upward&ndash;shift\" of the diastolic pressure&ndash;volume loop without a change in end-diastolic volume (",
"      <a class=\"graphic graphic_figure graphicRef79423 \" href=\"UTD.htm?22/34/23086\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diastolic dysfunction'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ross J Jr, Braunwald E. Control of cardiac performance. In: Handbook of Physiology, vol 1, The Heart, Williams &amp; Wilkins, Baltimore 1980. p.533.",
"    </li>",
"    <li>",
"     Braunwald E. Pathophysiology of heart failure. In: Heart Disease, 4th ed, Braunwald E (Ed), Saunders, Philadelphia 1992. p.393.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23076/abstract/3\">",
"      BADEER HS. CONTRACTILE TENSION IN THE MYOCARDIUM. Am Heart J 1963; 66:432.",
"     </a>",
"    </li>",
"    <li>",
"     Grossman W. Evaluation of systolic and diastolic function of the myocardium. In: Cardiac Catheterization and Angiography, 3d ed, Grossman W (Ed), Lea and Febiger, Philadelphia 1986. p.301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23076/abstract/5\">",
"      Litwin SE, Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol 1993; 22:49A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23076/abstract/6\">",
"      Holubarsch C, Ruf T, Goldstein DJ, et al. Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels. Circulation 1996; 94:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23076/abstract/7\">",
"      Schwinger RH, B&ouml;hm M, Koch A, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res 1994; 74:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23076/abstract/8\">",
"      Komamura K, Shannon RP, Ihara T, et al. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993; 265:H1119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3506 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23076=[""].join("\n");
var outline_f22_34_23076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1683611\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL LEFT VENTRICULAR PRESSURE-VOLUME RELATIONSHIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contractility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Afterload",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRESSURE-VOLUME RELATIONSHIPS IN HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1683611\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3506\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3506|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/10/25772\" title=\"figure 1\">",
"      LV pressure volume loop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/45/44765\" title=\"figure 2\">",
"      Sarcomere function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/50/39725\" title=\"figure 3\">",
"      Afterload and cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/56/33677\" title=\"figure 4\">",
"      Frank Starling curves in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/34/23086\" title=\"figure 5\">",
"      Systolic diastolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_34_23077="Transmetatarsal Lisfranc and Chopart amputations";
var content_f22_34_23077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Transmetatarsal, Lisfranc and Chopart amputations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23077=[""].join("\n");
var outline_f22_34_23077=null;
var title_f22_34_23078="In-line percutaneous transtracheal ventilationcontrol valve";
var content_f22_34_23078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    In-line commercially available percutaneous transtracheal ventilation control valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Positive pressure ventilation is administered by pressing and releasing the valve (or opening and occluding the Y-connector, three-way stopcock, etc.). If necessary, a standard self-inflating resuscitation bag can be used as a temporizing measure. B) Permanent in-line valve PTV system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mittal MK, Baren JM. Percutaneous Transtracheal Ventilation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23078=[""].join("\n");
var outline_f22_34_23078=null;
var title_f22_34_23079="Basic airway management in adults";
var content_f22_34_23079=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic airway management in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23079/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23079/contributors\">",
"     Kathleen A Wittels, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23079/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23079/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23079/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23079/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/34/23079/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bag-mask ventilation is the cornerstone of basic airway management and is not a skill easily mastered [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/1\">",
"     1",
"    </a>",
"    ]. This procedure is most often needed because of inadequate ventilation, which can result from impaired respiratory effort or airway obstruction. Basic airway interventions may also be needed to manage the patient with inadequate oxygenation and during cardiopulmonary resuscitation.",
"   </p>",
"   <p>",
"    This topic will review the essential techniques involved in basic airway management in adults. Airway management of children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .) Issues related to endotracheal intubation in adults and other advanced airway management techniques are discussed elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF INADEQUATE VENTILATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Respiratory effort",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate respiratory effort can result from intrinsic (eg, intracranial hemorrhage) or extrinsic (eg, opioid overdose) factors. Poor respiratory effort causing inadequate ventilation can be difficult to discern: it is often silent, and detection depends on close observation of chest wall movement. Thorough evaluation requires that the patient be undressed and the clinician observe the rate, pattern, and depth of breathing, use of accessory muscles, abnormal sounds, and signs of injury. Both laymen and health care professionals often fail to accurately determine the adequacy of respiratory effort [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue airway obstruction in the unconscious patient can occur by several mechanisms. These include prolapse of the tongue into the posterior pharynx and loss of muscular tone in the soft palate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Simple airway maneuvers, such as the head-tilt chin-lift or jaw-thrust with or without a head tilt, often ameliorate this problem quickly. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Airway maneuvers'",
"    </a>",
"    below.) Obstruction by foreign bodies, injured tissue, blood, and secretions can also occur.",
"   </p>",
"   <p>",
"    Noises produced by the obstructed upper airway often make such obstruction easier to detect than poor respiratory effort. As an example, snoring or gurgling noises may be heard when the upper airway becomes partially obstructed by soft tissue or liquid (eg, blood, emesis). Complete airway obstruction is silent but may manifest transiently as retractions of the accessory muscles of respiration (suprasternal, supraclavicular, intercostal, subcostal) or as cyanosis, until frank respiratory arrest supervenes.",
"   </p>",
"   <p>",
"    If the patient is making respiratory effort, but not adequately ventilating because of airway obstruction, the clinician must immediately attempt to determine the cause of the obstruction while taking measures to alleviate it. In a conscious adult, there are data supporting the efficacy of chest thrusts, back blows or slaps, and abdominal thrusts in relieving complete foreign body airway obstruction (FBAO) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The chance of relieving an FBAO may be highest when using a combination of these techniques. One study showed that 50 percent of airway obstruction episodes were not relieved by a single technique [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care recommend rapid-sequence abdominal thrusts followed by chest thrusts if unsuccessful. Chest thrusts are the initial recommended technique if one is unable to encircle the abdomen of the patient or if the patient is late in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/10\">",
"     10",
"    </a>",
"    ]. There have been several case reports of injuries (eg, gastric rupture) from abdominal thrusts, so a quick physical assessment after thrusts are performed is reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unresponsive patients with presumed FBAO should receive cardiopulmonary resuscitation (CPR), as chest thrusts in these patients may produce higher airway pressures when compared with abdominal thrusts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/14\">",
"     14",
"    </a>",
"    ]. The 2005 American Heart Association guidelines recommend that a blind finger sweep",
"    <strong>",
"     NOT",
"    </strong>",
"    be used in the unconscious patient with an obstructed airway unless during the course of CPR, solid material becomes visible in the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/10\">",
"     10",
"    </a>",
"    ]. This change from the 2000 Advanced Cardiac Life Support (ACLS) guidelines is based, in part, on multiple reports of injuries to the clinician's fingers and to the patient's oropharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AIRWAY MANEUVERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two positioning maneuvers can be performed to improve airflow in the patient receiving basic airway management: head-tilt chin-lift and jaw-thrust.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Head-tilt chin-lift",
"    </span>",
"    &nbsp;&mdash;&nbsp;The head-tilt chin-lift is the primary maneuver used in any patient in whom cervical spine injury is",
"    <strong>",
"     NOT",
"    </strong>",
"    a concern. In this technique, the clinician uses two hands to extend the patient's neck and open the airway. While one hand applies downward pressure to the patient's forehead, the tips of the index and middle finger of the second hand lift the mandible at the mentum, which lifts the tongue from the posterior pharynx (",
"    <a class=\"graphic graphic_picture graphicRef70710 \" href=\"UTD.htm?38/23/39282\">",
"     picture 1",
"    </a>",
"    ). This technique has been shown in multiple studies to improve airway patency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Jaw-thrust maneuver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The jaw-thrust maneuver is an effective airway technique, particularly in the patient in whom cervical spine injury is a concern. This maneuver moves the tongue anteriorly with the mandible, minimizing the tongue's ability to obstruct the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/18\">",
"     18",
"    </a>",
"    ]. With the patient supine and the clinician standing at the head of the bed, the technique is performed by placing the heels of both hands on the parieto-occipital areas on each side of the patient's head, then grasping the angles of the mandible with the index and long fingers, and displacing the jaw anteriorly (",
"    <a class=\"graphic graphic_picture graphicRef51547 \" href=\"UTD.htm?26/29/27103\">",
"     picture 2",
"    </a>",
"    ). The jaw thrust is the safest first approach to opening the airway of a casualty with a suspected neck injury because if properly performed, it can generally be accomplished without extending the neck.",
"   </p>",
"   <p>",
"    The reduced emphasis on the jaw-thrust technique in the current Advanced Cardiac Life Support (ACLS) guidelines has to do with reducing the complexity of cardiopulmonary resuscitation (CPR) for lay persons rather than opposition to its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cervical spine immobilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most airway maneuvers are associated with some movement of the cervical spine (c-spine) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Regardless of the maneuver chosen, the clinician must stabilize the c-spine in order to minimize head and neck movement in any patient with a possible c-spine injury. Failure to do so is associated with a 7 to 10-fold increase in neurologic injury among patients with c-spine trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/21\">",
"     21",
"    </a>",
"    ]. If sufficient personnel are present, manual in-line stabilization, rather than mechanical restraints, should be used to ensure c-spine stabilization. Cervical collars can interfere with airway maneuvers and have been shown to cause increased intracranial pressure (ICP) from partial obstruction of venous outflow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Collars may be removed, provided manual in-line stabilization is maintained continuously, while basic airway management is performed. If the collar is left in place, clinicians should either open or remove the front half to permit basic airway management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     AIRWAY ADJUNCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once an open airway has been established, it must be maintained. Oropharyngeal and nasopharyngeal airway devices are important adjuncts in achieving this goal. Both will prevent the tongue from occluding the airway and provide an open conduit for air to pass. Unless bag-mask ventilation is expected to be needed only transiently (eg, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    takes effect), we suggest an oropharyngeal airway (OPA) be placed whenever bag-mask ventilation is required. The OPA may be supplemented by one or even two nasopharyngeal airways. Neither of these airway devices will protect the trachea from aspiration of secretions or gastric contents. An endotracheal tube should be inserted as soon as possible in any patient unable to protect his or her airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oropharyngeal airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal airways (OPAs) should only be used in a deeply unresponsive patient who is unable to maintain his or her airway. In responsive patients, they can cause vomiting and aspiration. The OPA is a curved, firm, hollow tube, with a rectangular aperture that is used to maintain a conduit between the mouth and the glottis to prevent obstruction by the patient's tongue and other soft tissue. OPAs have a flange that when properly inserted, rests against the patient's lips to prevent inadvertent inward migration of the OPA. This flange does not interfere with forming an adequate seal from a face mask.",
"   </p>",
"   <p>",
"    OPAs come in multiple sizes (",
"    <a class=\"graphic graphic_picture graphicRef50230 \" href=\"UTD.htm?2/29/2527\">",
"     picture 3",
"    </a>",
"    ). A line between the posterior angles of the mandible approximates the plane of the posterior oropharynx. Therefore, a rough method for choosing the correct OPA size is to hold the airway beside the patient's mandible, orienting it with the flange at the patient's mouth and the tip directed toward the angle of the mandible. The tip of an appropriately sized OPA should just reach the angle of the patient's mandible (",
"    <a class=\"graphic graphic_picture graphicRef77645 \" href=\"UTD.htm?42/45/43728\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When inserting an OPA, the clinician must avoid pushing the tongue into the posterior pharynx. This can be accomplished by starting with the curve of the OPA inverted (ie, directed cephalad) and then rotating it 180 degrees as its tip reaches the posterior pharynx (",
"    <a class=\"graphic graphic_figure graphicRef62820 \" href=\"UTD.htm?14/26/14754\">",
"     figure 1",
"    </a>",
"    ). Alternatively, a tongue depressor can be used to move the tongue out of the way as the airway device is passed, or care can be taken not to push the tongue posteriorly with the tip of the OPA.",
"   </p>",
"   <p>",
"    Whichever technique is chosen, the clinician should be certain that the OPA is correctly positioned. If there are problems ventilating the patient after insertion, the OPA should be removed and reinserted. If ventilation problems persist, the clinician should verify the size of the OPA (often a larger OPA will succeed where a smaller one fails), and insert at least one nasopharyngeal airway. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Nasopharyngeal airway'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Potential hazards of using the OPA include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pushing the tongue posteriorly, thereby exacerbating the airway obstruction",
"     </li>",
"     <li>",
"      Using an incorrectly-sized device: too small a device is ineffective and can be lost in the oropharynx, possibly causing obstruction; too large a device can press against the epiglottis and obstruct the larynx",
"     </li>",
"     <li>",
"      Catching the tongue or lips (usually the lower lip) between the airway and the teeth, thereby traumatizing the soft tissue",
"     </li>",
"     <li>",
"      Using the device in a patient with intact airway reflexes, possibly inducing vomiting. The OPA must be removed if protective reflexes are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nasopharyngeal airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasopharyngeal airway (NPA) is a soft rubber or plastic hollow tube that is passed through the nose into the posterior pharynx. Patients tolerate NPAs more easily than OPAs, so NPAs can be used when the use of an OPA is difficult, such as when the patient's jaw is clenched or the patient is semiconscious and cannot tolerate an OPA.",
"   </p>",
"   <p>",
"    Also known as nasal trumpets, NPAs come in sizes based on their internal diameter. The larger that the internal diameter of the airway is, the longer the tube will be. A length of 8.0 to 9.0 cm is used for a large adult, 7.0 to 8.0 cm for a medium adult, and 6.0 to 7.0 cm for a small adult (",
"    <a class=\"graphic graphic_picture graphicRef69419 \" href=\"UTD.htm?32/48/33551\">",
"     picture 5",
"    </a>",
"    ). Selecting NPAs based on length, rather than diameter, improves accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/24\">",
"     24",
"    </a>",
"    ]. A rough method for choosing the correct NPA size is to hold the airway beside the patient's mandible, orienting it with the flared end at the tip of the patient's nose and the distal tip directed toward the angle of the mandible. The tip of an appropriately sized NPA should just reach the angle of the patient's mandible.",
"   </p>",
"   <p>",
"    Prior to insertion, the NPA should be coated with water-soluble lubricant or anesthetic jelly. Contact time is insufficient for anesthetic jelly to make insertion more comfortable, but may improve tolerance of the device after it is placed. The device is then inserted along the floor of the naris into the posterior pharynx behind the tongue (",
"    <a class=\"graphic graphic_picture graphicRef79849 \" href=\"UTD.htm?30/4/30786\">",
"     picture 6",
"    </a>",
"    ). Clinicians should note that the floor of the naris inclines in a caudad orientation approximately 15 degrees. The tube can be rotated slightly if resistance is encountered.",
"   </p>",
"   <p>",
"    Although there are two case reports of intracranial NPA placement in patients with basilar skull fractures, such extreme complications are rare and can only occur with devastating disruption of the basal skull, improper insertion technique (angling the NPA cephalad in the naris, instead of following the floor of the naris), or both [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/24\">",
"     24",
"    </a>",
"    ]. More common potential hazards of using the NPA include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using an airway that is too long: this may cause the tip to enter the esophagus, increasing gastric distention and decreasing ventilation during rescue efforts.",
"     </li>",
"     <li>",
"      Injury to the nasal mucosa causing bleeding: this occurs in 30 percent of insertions and can lead to aspiration of blood or clots [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BAG-MASK VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bag-mask ventilation is a crucial airway management skill and one of the most difficult to perform correctly. The clinician performing bag-mask ventilation must carefully monitor the adequacy of his or her technique at all times. Properly performed bag-mask ventilation enables clinicians to provide adequate ventilation and oxygenation to a patient requiring airway support. This in turn gives the clinician sufficient time to pursue a controlled, well-planned approach to definitive airway management, such as endotracheal (ET) intubation.",
"   </p>",
"   <p>",
"    Successful bag-mask ventilation depends on three things: a patent airway, an adequate mask seal, and proper ventilation (ie, proper volume, rate, and cadence). Airway patency is obtained using airway maneuvers and adjuncts. Whenever possible, a two-handed technique is preferred for bag-mask ventilation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Airway maneuvers'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Airway adjuncts'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mask placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to placing the mask on a patient's face, the airway should be opened using the airway maneuvers and devices discussed above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Airway maneuvers'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Airway adjuncts'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once the airway is open, the next step is to correctly position the mask on the patient's face. The bag is detached from the mask prior to mask positioning. Having a large, heavy bag pulling on one end of the mask is a common error that unnecessarily complicates proper placement. The nasal portion of the mask should be spread slightly and placed on the bridge of the patient's nose. The body of the mask is then placed onto the patient's face covering the nose and mouth. The three facial landmarks that must be covered by the mask are the bridge of the nose, the two malar eminences, and the mandibular alveolar ridge [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/26\">",
"     26",
"    </a>",
"    ]. Neither the provider's wrists nor the mask cushion should rest on the patient's eyes during bag-mask ventilation as this can cause a vagal response or damage to the eyes.",
"   </p>",
"   <p>",
"    There are two methods for holding the mask in place: the single-hand (one hand, one person) mask hold and the two-hand (two hand, two person) mask hold. Although the two-hand mask hold is most effective, it requires a second clinician. Therefore, it is important to be comfortable with both techniques. When ventilation using a one hand, one person technique is unsuccessful, despite oral and nasal airway placement, a two hand, two person technique should be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Single-hand technique for bag-mask ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One hand is placed on the mask with the web space between the thumb and index finger resting against the mask connector. The web space is placed in the center of the mask, allowing for a more even application of pressure (",
"    <a class=\"graphic graphic_picture graphicRef80091 \" href=\"UTD.htm?29/44/30404\">",
"     picture 7",
"    </a>",
"    ). Force should not be exerted via the palm of the hand because it is off center and more likely to produce an air leak.",
"   </p>",
"   <p>",
"    The other three fingers (ie, middle, ring, and little) are placed along the mandible and pull the mandible up into the mask in a chin-lift maneuver, allowing the airway to open further. Those with larger hands can place the little finger posterior to the angle of the mandible and perform a jaw-thrust, although this is tiring to the hand. The correct technique is to lift the mandible up into the mask with the middle, ring, and little fingers while holding the mask tightly against the patient's face with the thumb and index finger (",
"    <a class=\"graphic graphic_picture graphicRef80091 \" href=\"UTD.htm?29/44/30404\">",
"     picture 7",
"    </a>",
"    ). Clinicians should take care to pull up only on the bony parts of the mandible: pressure to the soft tissues of the neck may occlude the airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Two-hand technique for bag-mask ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two-hand mask hold requires two providers, but it is the most effective method of opening the patient's airway while maintaining an adequate mask seal and minimizing provider fatigue. With this technique, one provider's sole responsibility is to use both hands to create a good mask seal and to maintain an open airway. Another provider squeezes the bag to ventilate the patient. Proper placement and holding of the mask are essential for a good seal and are the most difficult aspects of bag-mask ventilation. The most experienced airway manager available should therefore control the mask.",
"   </p>",
"   <p>",
"    There are two ways to position the hands. In the more traditional method, both thumbs and index fingers hold pressure along the inferior and superior ridges of the mask (",
"    <a class=\"graphic graphic_picture graphicRef82048 \" href=\"UTD.htm?30/30/31204\">",
"     picture 8",
"    </a>",
"    ). The other three fingers on each hand hold the mandible, in a fashion similar to the one-handed mask hold, and perform a simultaneous chin-lift and jaw-thrust maneuver. This position may not be comfortable to maintain for long periods of time.",
"   </p>",
"   <p>",
"    We recommend another method of two-handed mask technique that uses the stronger thenar eminences to hold the mask in place. The thenar eminences are positioned parallel to each other along the long axis of each side of the mask, allowing the four remaining fingers to provide chin-lift and jaw-thrust maneuvers (",
"    <a class=\"graphic graphic_picture graphicRef82048 \" href=\"UTD.htm?30/30/31204\">",
"     picture 8",
"    </a>",
"    ). This technique is easier to perform, allows stronger hand muscles to maintain a proper seal, minimizes provider fatigue, and enables four fingers to perform the chin-lift and jaw-thrust.",
"   </p>",
"   <p>",
"    In a crossover randomized trial of 42 elective surgery patients, two-handed bag-mask ventilation provided greater minute ventilation and tidal volumes and fewer episodes of inadequate ventilation compared to a one-handed technique [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Trouble-shooting problems with bag-mask ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When obstruction to air flow exists or the chest does not rise, the clinician should first consider the most common causes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate mask seal: patients with facial hair may need KY jelly or water applied to improve the seal; edentulous patients should have their false teeth reinserted [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/28\">",
"       28",
"      </a>",
"      ] or their cheeks expanded with 4 x 4 gauze. Lower lip placement, in which the caudad end of the face mask is positioned between the lower lip and the alveolar ridge, may improve ventilation in edentulous patients (",
"      <a class=\"graphic graphic_picture graphicRef87227 \" href=\"UTD.htm?30/62/31716\">",
"       picture 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/29\">",
"       29",
"      </a>",
"      ]. In one observational study of 49 edentulous patients with a substantial air leak during two-handed bag-mask ventilation performed in the operating room, use of the lower lip technique reduced the median air leak by 95 percent.",
"     </li>",
"     <li>",
"      Improper mask size: ensure that the corners of the mouth and all airway adjuncts are inside the body of the mask,",
"      <strong>",
"       NOT",
"      </strong>",
"      creating a leak by interfering with mask seal.",
"     </li>",
"     <li>",
"      Lack of airway adjuncts (ie, nasopharyngeal and oropharyngeal airways): verify that airway adjuncts are being utilized and in proper position.",
"     </li>",
"     <li>",
"      Inadequate airway maneuvers: ensure the jaw-thrust and other maneuvers are being done effectively in order to open the airway.",
"     </li>",
"     <li>",
"      Inexperienced personnel: determine if a more experienced clinician needs to be recruited to help provide optimal bag-mask technique, particularly mask seal [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors associated with difficult bag mask ventilation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link&amp;anchor=H14#H14\">",
"     \"The difficult airway in adults\", section on 'Difficult bag-mask ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ventilation volumes, rates, and cadence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once an open airway and a good mask seal are present, the clinician connects the bag to the mask and ventilates the patient. Three critical errors should be avoided:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Giving excessive tidal volumes",
"     </li>",
"     <li>",
"      Forcing air too quickly",
"     </li>",
"     <li>",
"      Ventilating too rapidly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A volume just large enough to cause chest rise (no more than 8 to 10",
"    <span class=\"nowrap\">",
"     cc/kg)",
"    </span>",
"    should be used. During cardiopulmonary resuscitation (CPR), even smaller tidal volumes are adequate (5 to 6",
"    <span class=\"nowrap\">",
"     cc/kg)",
"    </span>",
"    due to the reduced cardiac output of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/30\">",
"     30",
"    </a>",
"    ]. The bag should not be squeezed explosively. It should be squeezed steadily over approximately one full second. This technique, in addition to producing smaller tidal volumes, reduces the likelihood of creating sufficient pressure to open the gastroesophageal sphincter, which leads to gastric inflation. The ventilatory rate should not exceed 10 to 12 breaths per minute.",
"   </p>",
"   <p>",
"    These important concepts are based on multiple randomized controlled studies in animals and observational studies in humans showing that the use of larger tidal volumes and ventilation rates is associated with increased intrathoracic pressures, which compromise both coronary and cerebral perfusion pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23079/abstract/31-35\">",
"     31-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cricoid pressure (Sellicks maneuver)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sellicks maneuver (ie, firm cricoid pressure) may reduce gastric insufflation during bag-mask ventilation, and it is reasonable to apply it during BMV if adequate personnel are available. The technique and its role in rapid sequence intubation are controversial and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link&amp;anchor=H12#H12\">",
"     \"Rapid sequence intubation in adults\", section on 'Protection (cricoid pressure) and positioning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor respiratory effort causing inadequate ventilation can be difficult to discern: it is often silent and requires close observation of chest wall movement. The most common cause of airway occlusion in an unconscious patient is prolapse of the tongue into the posterior pharynx. This problem can often be corrected quickly using simple airway maneuvers such as the head-tilt chin-lift or jaw-thrust with or without a head-tilt. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes of inadequate ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positioning maneuvers, including head-tilt chin-lift and jaw-thrust, can be performed to improve airflow in the patient receiving basic airway management. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Airway maneuvers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oropharyngeal airway (OPA) and nasopharyngeal airway (NPA) devices are important adjuncts for maintaining an open airway. Unlike a cuffed endotracheal (ET) tube, neither one protects the trachea from aspiration of secretions or gastric contents. An ET tube should be inserted as soon as possible in any patient unable to protect his or her airway. Proper insertion technique and appropriately sized devices are essential to the successful use of OPAs and NPAs. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Oropharyngeal airway'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Nasopharyngeal airway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bag-mask ventilation is a crucial airway management skill and one of the most difficult to perform correctly. The clinician performing bag-mask ventilation must carefully monitor the adequacy of his or her technique at all times. Proper bag-mask technique enables clinicians to provide adequate ventilation and oxygenation to a patient requiring airway support and is described above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bag-mask ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful bag-mask ventilation depends on three things: a patent airway, an adequate mask seal, and proper ventilation (ie, proper volumes, rates, and cadence). Airway patency is obtained using airway maneuvers and adjuncts. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Airway maneuvers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Airway adjuncts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper placement and holding of the mask is essential for a good seal. Whenever possible, clinicians should use the two-hand technique that makes use of the thenar eminences to hold the mask in place. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Two-hand technique for bag-mask ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Problems commonly encountered during bag-mask ventilation include: inadequate mask seal, improper mask size, lack of airway adjuncts (ie, nasopharyngeal and oropharyngeal airways), and inadequate airway maneuvers. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Trouble-shooting problems with bag-mask ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When performing bag-mask ventilation, clinicians must avoid three critical errors: giving excessive tidal volumes, forcing air too quickly, and ventilating too rapidly. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Ventilation volumes, rates, and cadence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/1\">",
"      Komatsu R, Kasuya Y, Yogo H, et al. Learning curves for bag-and-mask ventilation and orotracheal intubation: an application of the cumulative sum method. Anesthesiology 2010; 112:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/2\">",
"      Ruppert M, Reith MW, Widmann JH, et al. Checking for breathing: evaluation of the diagnostic capability of emergency medical services personnel, physicians, medical students, and medical laypersons. Ann Emerg Med 1999; 34:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/3\">",
"      Vargo JJ, Zuccaro G Jr, Dumot JA, et al. Automated graphic assessment of respiratory activity is superior to pulse oximetry and visual assessment for the detection of early respiratory depression during therapeutic upper endoscopy. Gastrointest Endosc 2002; 55:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/4\">",
"      Shorten GD, Opie NJ, Graziotti P, et al. Assessment of upper airway anatomy in awake, sedated and anaesthetised patients using magnetic resonance imaging. Anaesth Intensive Care 1994; 22:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/5\">",
"      Mathru M, Esch O, Lang J, et al. Magnetic resonance imaging of the upper airway. Effects of propofol anesthesia and nasal continuous positive airway pressure in humans. Anesthesiology 1996; 84:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/6\">",
"      Heimlich HJ. A life-saving maneuver to prevent food-choking. JAMA 1975; 234:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/7\">",
"      Ingalls TH. Heimlich versus a slap on the back. N Engl J Med 1979; 300:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/8\">",
"      Skulberg A. Chest compression--an alternative to the Heimlich manoeuver? Resuscitation 1992; 24:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/9\">",
"      Redding JS. The choking controversy: critique of evidence on the Heimlich maneuver. Crit Care Med 1979; 7:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/10\">",
"      2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112 (Suppl I):IV.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/11\">",
"      Gallardo A, Rosado R, Ram&iacute;rez D, et al. Rupture of the lesser gastric curvature after a Heimlich maneuver. Surg Endosc 2003; 17:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/12\">",
"      Majumdar A, Sedman PC. Gastric rupture secondary to successful Heimlich manoeuvre. Postgrad Med J 1998; 74:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/13\">",
"      Dupre MW, Silva E, Brotman S. Traumatic rupture of the stomach secondary to Heimlich maneuver. Am J Emerg Med 1993; 11:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/14\">",
"      Langhelle A, Sunde K, Wik L, Steen PA. Airway pressure with chest compressions versus Heimlich manoeuvre in recently dead adults with complete airway obstruction. Resuscitation 2000; 44:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/15\">",
"      RUBEN HM, ELAM JO, RUBEN AM, GREENE DG. Investigation of upper airway problems in resuscitation. 1. Studies of pharyngeal x-rays and performance by laymen. Anesthesiology 1961; 22:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/16\">",
"      Kabbani M, Goodwin SR. Traumatic epiglottis following blind finger sweep to remove a pharyngeal foreign body. Clin Pediatr (Phila) 1995; 34:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/17\">",
"      Guildner CW. Resuscitation--opening the airway. A comparative study of techniques for opening an airway obstructed by the tongue. JACEP 1976; 5:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/18\">",
"      Uzun L, Ugur MB, Altunkaya H, et al. Effectiveness of the jaw-thrust maneuver in opening the airway: a flexible fiberoptic endoscopic study. ORL J Otorhinolaryngol Relat Spec 2005; 67:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/19\">",
"      Donaldson WF 3rd, Heil BV, Donaldson VP, Silvaggio VJ. The effect of airway maneuvers on the unstable C1-C2 segment. A cadaver study. Spine (Phila Pa 1976) 1997; 22:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/20\">",
"      Brimacombe J, Keller C, K&uuml;nzel KH, et al. Cervical spine motion during airway management: a cinefluoroscopic study of the posteriorly destabilized third cervical vertebrae in human cadavers. Anesth Analg 2000; 91:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/21\">",
"      Reid DC, Henderson R, Saboe L, Miller JD. Etiology and clinical course of missed spine fractures. J Trauma 1987; 27:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/22\">",
"      Kolb JC, Summers RL, Galli RL. Cervical collar-induced changes in intracranial pressure. Am J Emerg Med 1999; 17:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/23\">",
"      Mobbs RJ, Stoodley MA, Fuller J. Effect of cervical hard collar on intracranial pressure after head injury. ANZ J Surg 2002; 72:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/24\">",
"      Roberts K, Whalley H, Bleetman A. The nasopharyngeal airway: dispelling myths and establishing the facts. Emerg Med J 2005; 22:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/25\">",
"      Stoneham MD. The nasopharyngeal airway. Assessment of position by fibreoptic laryngoscopy. Anaesthesia 1993; 48:575.",
"     </a>",
"    </li>",
"    <li>",
"     Schneider, RE, Murphy, MF. Bag/mask ventilation and endotracheal intubation. In: Manual of Emergency Airway Management, Walls, RM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2004. p.43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/27\">",
"      Joffe AM, Hetzel S, Liew EC. A two-handed jaw-thrust technique is superior to the one-handed \"EC-clamp\" technique for mask ventilation in the apneic unconscious person. Anesthesiology 2010; 113:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/28\">",
"      Conlon NP, Sullivan RP, Herbison PG, et al. The effect of leaving dentures in place on bag-mask ventilation at induction of general anesthesia. Anesth Analg 2007; 105:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/29\">",
"      Racine SX, Solis A, Hamou NA, et al. Face mask ventilation in edentulous patients: a comparison of mandibular groove and lower lip placement. Anesthesiology 2010; 112:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/30\">",
"      Paradis NA, Martin GB, Goetting MG, et al. Simultaneous aortic, jugular bulb, and right atrial pressures during cardiopulmonary resuscitation in humans. Insights into mechanisms. Circulation 1989; 80:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/31\">",
"      Aufderheide TP, Sigurdsson G, Pirrallo RG, et al. Hyperventilation-induced hypotension during cardiopulmonary resuscitation. Circulation 2004; 109:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/32\">",
"      2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care With Treatment Recommendations. Circulation 2005; 112 (suppl I):III.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/33\">",
"      Bowman FP, Menegazzi JJ, Check BD, Duckett TM. Lower esophageal sphincter pressure during prolonged cardiac arrest and resuscitation. Ann Emerg Med 1995; 26:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/34\">",
"      Aufderheide TP, Lurie KG. Death by hyperventilation: a common and life-threatening problem during cardiopulmonary resuscitation. Crit Care Med 2004; 32:S345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23079/abstract/35\">",
"      Yannopoulos D, Tang W, Roussos C, et al. Reducing ventilation frequency during cardiopulmonary resuscitation in a porcine model of cardiac arrest. Respir Care 2005; 50:628.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 267 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23079=[""].join("\n");
var outline_f22_34_23079=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF INADEQUATE VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Respiratory effort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AIRWAY MANEUVERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Head-tilt chin-lift",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Jaw-thrust maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AIRWAY ADJUNCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oropharyngeal airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nasopharyngeal airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BAG-MASK VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mask placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Single-hand technique for bag-mask ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Two-hand technique for bag-mask ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Trouble-shooting problems with bag-mask ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ventilation volumes, rates, and cadence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cricoid pressure (Sellicks maneuver)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/267\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/267|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/26/14754\" title=\"figure 1\">",
"      Oropharyn airway insert",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/267|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/23/39282\" title=\"picture 1\">",
"      Head-tilt chin-lift maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/29/27103\" title=\"picture 2\">",
"      Jaw thrust maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/29/2527\" title=\"picture 3\">",
"      Oropharyngeal airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/45/43728\" title=\"picture 4\">",
"      Orophyarngeal airway sizing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/48/33551\" title=\"picture 5\">",
"      Nasopharyngeal airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/4/30786\" title=\"picture 6\">",
"      Nasopharyngeal airway insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/44/30404\" title=\"picture 7\">",
"      One hand bag mask ventilation technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/30/31204\" title=\"picture 8\">",
"      Two handed tech",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/62/31716\" title=\"picture 9\">",
"      Bag mask technique for edentulous patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_34_23080="Dexamethasone to prevent neurologic complications of bacterial meningitis in adults";
var content_f22_34_23080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dexamethasone to prevent neurologic complications of bacterial meningitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23080/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23080/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23080/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23080/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/34/23080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis continues to result in substantial morbidity and mortality despite the availability of effective antimicrobial therapy. The risk of dying or of developing complications is related to the age and general health of the patient, the causative pathogen, the severity and duration of illness at the time of presentation, and, occasionally, to delays in the initiation of antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early intravenous administration of glucocorticoids (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) has been evaluated as adjuvant therapy in an attempt to diminish the rate of hearing loss and other neurologic complications as well as mortality in selected patients with bacterial meningitis. The possible protective role of dexamethasone therapy to prevent neurologic complications in selected adult patients will be reviewed here. The neurologic complications of meningitis in adults and more general issues, such as the clinical manifestations, diagnosis, treatment, and prognosis of bacterial meningitis in adults, as well as neurologic complications and the role of dexamethasone in neonates and children with bacterial meningitis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=see_link\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94225221\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF BACTERIAL MENINGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications due to bacterial meningitis can be divided into systemic and neurologic. Systemic complications such as septic shock, disseminated intravascular coagulation, acute respiratory distress syndrome, and septic or reactive arthritis, are usually the consequence of the bacteremia that frequently accompanies meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic complications of bacterial meningitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired mental status",
"     </li>",
"     <li>",
"      Increased intracranial pressure and cerebral edema",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Focal neurologic deficits (eg, cranial nerve palsy, hemiparesis)",
"     </li>",
"     <li>",
"      Cerebrovascular abnormalities",
"     </li>",
"     <li>",
"      Sensorineural hearing loss",
"     </li>",
"     <li>",
"      Intellectual impairment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications may be sudden or gradual in onset and can appear at any time after the onset of symptoms, including after the completion of therapy. Although many neurologic complications are severe, others, such as hearing loss, may be subtle or inapparent during the early phases of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94225420\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early intravenous administration of glucocorticoids (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) has been evaluated as adjuvant therapy in an attempt to diminish the rate of hearing loss and other neurologic complications as well as mortality in selected patients with bacterial meningitis. The rationale for this approach is provided by animal studies showing that hearing loss is temporally associated with the severe inflammatory changes induced by bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/2\">",
"     2",
"    </a>",
"    ] and that dexamethasone reduces CSF synthesis of cytokines (such as tumor necrosis factor-alpha and interleukin-1), CSF inflammation, and cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=see_link&amp;anchor=H12#H12\">",
"     \"Neurologic complications of bacterial meningitis in adults\", section on 'Sensorineural hearing loss'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized trial of patients in Vietnam with bacterial meningitis, those who received adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    had lower CSF opening pressures, higher CSF:plasma glucose ratios, and lower CSF concentrations of the cytokines interleukin (IL)-6, IL-8, and IL-10 compared with patients who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy for bacterial meningitis have been performed in both developed and developing countries with inconsistent results. An additional issue is the possible effect of such therapy on the penetration of antibiotics into the cerebrospinal fluid (CSF).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     In developed regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in adults with bacterial meningitis in the developed world was best evaluated in a randomized, double-blind trial in 301 patients from Europe with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/8\">",
"     8",
"    </a>",
"    ]. The median duration of symptoms prior to treatment was 24 hours.",
"   </p>",
"   <p>",
"    All patients had suspected meningitis in combination with one or more of the following findings on CSF analysis: cloudy fluid, a positive Gram stain for bacteria (seen in 74 percent),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a CSF white cell count above",
"    <span class=\"nowrap\">",
"     1000/microL.",
"    </span>",
"    CSF culture revealed S. pneumoniae in 36 percent, N. meningitidis in 32 percent, other bacteria in 10 percent, and no bacteria in 21 percent.",
"   </p>",
"   <p>",
"    The patients were randomly assigned to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (10 mg every six hours for four days) or placebo with the first dose administered 15 to 20 minutes before or at the time of antibiotic administration. Most patients were initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    as a single agent and no pneumococcal isolates resistant to penicillin were detected among the 78 of 108 isolates upon which susceptibility testing was performed.",
"   </p>",
"   <p>",
"    The primary end point was all unfavorable outcomes (death or neurologic disability) at eight weeks. Secondary outcomes were focal neurologic deficits, hearing loss, and side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy, such as gastrointestinal bleeding, fungal infection, Herpes zoster, and hyperglycemia.",
"   </p>",
"   <p>",
"    The following findings were noted at eight weeks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      significantly reduced both mortality (7 versus 15 percent with placebo, relative risk [RR] 0.48, 95% CI 0.24-0.96) and all unfavorable outcomes (15 versus 25 percent, RR 0.59, 95% CI 0.37-0.94).",
"     </li>",
"     <li>",
"      When the outcomes were analyzed based upon culture results (S. pneumoniae, N. meningitidis, other bacteria, or negative bacterial culture), significant reductions in mortality (14 versus 34 percent) and all unfavorable outcomes (26 versus 52 percent) were only seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      therapy in patients with S. pneumoniae meningitis. Patients who did not have pneumococcal meningitis (most often meningococcal meningitis) had much lower rates of both mortality (4 percent) and all unfavorable outcomes (9 percent), independent of whether or not they received dexamethasone therapy. General issues related to mortality in patients with bacterial meningitis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link&amp;anchor=H31#H31\">",
"       \"Initial therapy and prognosis of bacterial meningitis in adults\", section on 'Mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among the patients with pneumococcal meningitis, significant benefit was seen only in those with an intermediate neurologic deficit on admission, defined as a Glasgow coma scale of 8 to 11 (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      ). In such patients, the rate of unfavorable outcomes at eight weeks was reduced in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      group (22 versus 52 percent, relative risk 0.43, 95% CI 0.19-0.95). There was no evidence of benefit among patients with a mild neurologic deficit.",
"     </li>",
"     <li>",
"      In a subset analysis of patients with pneumococcal meningitis, the mortality benefit seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      was entirely due to reduced mortality from a systemic cause such as septic shock, pneumonia, or acute respiratory distress syndrome (2 versus 16 percent without dexamethasone); there was no significant reduction in mortality due to neurologic causes (7 versus 10 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was no increase in gastrointestinal bleeding with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A follow-up study at a median of over eight years evaluated the long-term effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    on neurologic sequelae in 87 of 99 eligible patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/10\">",
"     10",
"    </a>",
"    ]. There was no difference between the treatment groups with regard to persistent cognitive dysfunction, hearing loss, or focal neurologic deficits. It is possible that the trial was underpowered to detect benefits of this magnitude. In addition, these neurologic sequelae primarily occurred in the most severely ill patients; the proportion of patients who survived to be tested was significantly greater in the dexamethasone group.",
"   </p>",
"   <p>",
"    An additional finding was that patients with pneumococcal meningitis had a significantly higher rate of persistent cognitive dysfunction compared with other patients (21 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/10\">",
"     10",
"    </a>",
"    ]. This observation is consistent with the worse outcomes at eight weeks cited above in the patients with pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nationwide prospective cohort study was subsequently undertaken in the Netherlands to evaluate the implementation of adjunctive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    use in adults with pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/11\">",
"     11",
"    </a>",
"    ]. Dexamethasone was initiated with or before the first dose of antibiotics in 84 percent of 357 patients with pneumococcal meningitis in 2006-2009, but in only 3 percent of 352 patients in 1998-2002. At hospital discharge, an unfavorable outcome (defined as Glasgow coma score of 1 to 4 points) was present in 39 percent of patients in the 2006-2009 cohort compared with 50 percent of patients in the 1998-2002 cohort (odds ratio 0.63, 95% CI 0.46-0.86). Rates of death (20 versus 30 percent) and hearing loss (12 versus 22 percent) were significantly lower in the 2006-2009 cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     In developing regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the results of the above trial, which involved patients with bacterial meningitis in the developed world, a study from sub-Saharan Africa found no benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/12\">",
"     12",
"    </a>",
"    ]. In this randomized trial of adults in Malawi, 465 patients (95 percent of whom were HIV-positive) received dexamethasone or placebo for four days plus intravenous or intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In an intention-to-treat analysis, there was no significant mortality difference at 40 days in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    group as compared with the placebo group (56 versus 53 percent, odds ratio 1.14, 95% CI 0.79 to 1.64). There was also no difference in mortality when the analysis was restricted to patients with pneumococcal meningitis (53 versus 50 percent, odds ratio 1.10; 95% CI 0.68 to 1.77), and there were no significant differences between the two groups in the outcomes of disability and death combined, hearing loss, and adverse events.",
"   </p>",
"   <p>",
"    There are several issues that must be considered in the interpretation of these results. In Malawi, the outcomes of bacterial meningitis are poor and the life expectancy in low. Contributing factors to worse outcomes in these patients include poor nutrition, delays in presentation that may have contributed to neurologic compromise prior to treatment, and chronic diseases such as HIV.",
"   </p>",
"   <p>",
"    A similar prospective, randomized, double-blind trial of 435 Vietnamese patients (of whom less than 1 percent were HIV positive), found no overall reduction in mortality or disability with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy compared with placebo started before the first dose of antibiotics (intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/13\">",
"     13",
"    </a>",
"    ]. However, when the analysis was limited to the 300 patients (69 percent) with confirmed bacterial meningitis (ie, those with organisms cultured from CSF or blood or detected in CSF), there was a significant reduction in the risk of death at one month (relative risk, 0.43; 95% CI 0.20 to 0.94) and in the risk of death or disability at six months (odds ratio 0.56; 95% CI 0.32 to 0.98). The major causes of confirmed bacterial meningitis were Streptococcus suis (39 percent), S. pneumoniae (18 percent), Neisseria meningitis (6 percent), and other gram-negative organisms (10 percent). The outcomes were significantly worse in patients with confirmed meningitis caused by a bacterium other than S. suis, who had a mortality rate of 2.6 percent. The median duration of symptoms prior to therapy was three to four days in this study cohort.",
"   </p>",
"   <p>",
"    Patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for probable bacterial meningitis (defined as the presence of a typical clinical picture and lack of an alternative diagnosis in the absence of identification of bacteria in CSF or blood) had an increased risk of death at one month. The authors proposed that this finding could be explained by the inadvertent inclusion of cases of tuberculous meningitis in the treatment group. Eleven individuals in the study (eight in the dexamethasone group and three in the placebo group) were subsequently treated for tuberculous meningitis on clinical grounds. Six of these patients died, all of whom had received dexamethasone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1326228962\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four separate meta-analyses have been performed using data collected in various randomized controlled trials of glucocorticoid treatment of bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. The latest of these studies included data from 4041 individual patients entered into 24 randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/17\">",
"     17",
"    </a>",
"    ]. The patient populations in the trials analyzed were heterogeneous (children and adults, developing world and developed world). This meta-analysis showed the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in mortality between patients who received glucocorticoids and those who did not, although there was a trend towards decreased mortality in adults who received glucocorticoids (relative risk [RR] 0.74, 95% CI 0.53-1.05). In sub-group analyses that evaluated high-income countries and low-income countries separately, no mortality benefit was observed in either group.",
"     </li>",
"     <li>",
"      A subgroup analysis showed that glucocorticoids reduced mortality in patients with Streptococcus pneumoniae meningitis (RR 0.84, 95% CI 0.72-0.98).",
"     </li>",
"     <li>",
"      Glucocorticoids were associated with lower rates of severe hearing loss (RR 0.67, 95% CI 0.51-0.88), any hearing loss (RR 0.76, 95% CI 0.64-0.89), and short-term neurologic sequelae other than hearing loss (RR 0.83, 95% CI 0.69-1.00). There was no difference in long-term neurologic sequelae between glucocorticoid-treated patients and controls (RR 0.90, 95% CI 0.74-1.10). In a subgroup analysis for study quality, glucocorticoids had no effect on severe hearing loss in high quality studies.",
"     </li>",
"     <li>",
"      In high-income countries, glucocorticoids reduced severe hearing loss (RR 0.51, 95% CI 0.35-0.7), any hearing loss (RR 0.58, 95% CI 0.45-0.73), and short-term neurologic sequelae (RR 0.64, 95% CI 0.48-0.85). In contrast, in low-income countries, glucocorticoids conferred none of these beneficial effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This meta-analysis suggests that glucocorticoids reduce mortality only in patients with S. pneumoniae meningitis. It also suggests that glucocorticoids reduce hearing loss and short-term neurologic sequelae among patients in high-income countries, but not among patients in low-income countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect on antibiotic regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a potential problem with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in patients with possible penicillin-resistant pneumococcal meningitis. Such patients are typically treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    pending susceptibility results. However, the entry of vancomycin into the CSF may be reduced by the decrease in inflammation with dexamethasone.",
"   </p>",
"   <p>",
"    This issue was addressed in a rabbit model of penicillin- and cephalosporin-resistant pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    substantially reduced the penetration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    into the CSF, resulting in a delay in CSF sterilization that was not seen in rabbits not treated with dexamethasone. In comparison,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    penetration into the CSF was not affected by dexamethasone and the combination of rifampin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    produced prompt bacteriologic cure.",
"   </p>",
"   <p>",
"    The applicability of these experimental findings in rabbits to bacterial meningitis in humans in uncertain. Therapeutic CSF concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    in the CSF were evaluated in a study of 14 adults with bacterial meningitis, 13 of whom had pneumococcal meningitis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and vancomycin (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose followed by a continuous infusion of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in adults) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/19\">",
"     19",
"    </a>",
"    ]. The mean CSF vancomycin concentration was 7.9",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (range 3.1 to 22.3",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    which is higher than the MIC of vancomycin for S. pneumoniae (0.25 to 1.0",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CSF",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    concentrations were directly related to the serum vancomycin concentrations, suggesting that high doses of vancomycin are required to achieve effective CSF vancomycin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/19\">",
"     19",
"    </a>",
"    ]. However, it is not certain how the findings with a constant vancomycin infusion used in this study apply to the more common regimen of two to four divided daily doses. Furthermore, since there was no control group, this study did not address the issue of whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    interferes with vancomycin penetration into the CSF.",
"   </p>",
"   <p>",
"    The recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    in the 2004 IDSA practice guidelines is 30 to 45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/20\">",
"     20",
"    </a>",
"    ]. However, initial treatment failures have occurred in adults treated solely with vancomycin at a dose of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/21\">",
"     21",
"    </a>",
"    ]. For the treatment of bacterial meningitis, vancomycin should be dosed to achieve target serum trough concentrations of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Appropriate initial dosing of vancomycin is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\", section on 'First-line regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of antibiotic regimen in patients with bacterial meningitis who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    is described below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Antibiotic regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy in patients with bacterial meningitis varies in developed and developing countries and with the offending organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Developed regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon data reported in the single large randomized trial cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/8\">",
"     8",
"    </a>",
"    ] as well as the 2010 meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/17\">",
"     17",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    therapy is appropriate in adults in developed countries with known or suspected pneumococcal meningitis and a Glasgow coma scale score of 8 to 11 (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the 2004 Infectious Diseases Society of America (IDSA) guidelines for the management of bacterial meningitis recommend that adjunctive dexamethasone be initiated in ALL adults with suspected or proven pneumococcal meningitis because assessment of the Glasgow coma scale score may delay the initiation of appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/20\">",
"     20",
"    </a>",
"    ]. We agree with the guidelines, and therefore recommend dexamethasone therapy in adults in developed countries with known or suspected pneumococcal meningitis regardless of the Glasgow coma scale score.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    should be continued for four days if the Gram stain reveals organisms consistent with S. pneumoniae or if the CSF or blood culture grows S. pneumoniae. Dexamethasone should be discontinued if the Gram stain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cultures reveal another pathogen or if bacterial meningitis is subsequently thought not to be present. There is no proven benefit from dexamethasone therapy for adult patients with meningitis due to other pathogens, mostly meningococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/8\">",
"     8",
"    </a>",
"    ], but also including gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\", section on 'Role of dexamethasone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    regimen is 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every six hours for four days [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/20\">",
"     20",
"    </a>",
"    ]. Dexamethasone should be initiated shortly before or at the same time as the first dose of antibiotics. In a review that included 118 episodes of community-acquired bacterial meningitis in adults in which dexamethasone was given, the likelihood of an unfavorable outcome was much higher in the 94 patients in whom dexamethasone was given after antibiotics (51 versus 12 percent if given before antibiotics) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, we suggest that adjunctive dexamethasone NOT be given to adults who have already received antimicrobial therapy because it is unlikely to improve patient outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Developing regions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in developing regions is less clear than for developed countries. In regions with high HIV prevalence, high rates of malnutrition, and delayed clinical presentation such as Africa, there does not appear to be any clinical benefit to the administration of dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. In other regions, we suggest administering dexamethasone in patients who have bacterial meningitis confirmed by Gram stain or a rapid diagnostic test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/13,24\">",
"     13,24",
"    </a>",
"    ]. We suggest the regimen used in the Vietnamese trial (0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours for four days) starting before the first dose of antibiotics. In some areas of the developing world, however, it is not possible to get microbiological test results in a prompt fashion. Thus, empirically administering adjunctive dexamethasone is reasonable in patients in whom there is a strong clinical suspicion for acute bacterial meningitis until microbiologic results are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotic regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the uncertainty of the magnitude of the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    on the CSF penetration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , there are two reasonable therapeutic options when adults with confirmed or possible pneumococcal meningitis are treated with dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Effect on antibiotic regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Begin with a regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      . If susceptibility studies show intermediate susceptibility (MIC &ge;2",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      to ceftriaxone and cefotaxime,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      is added [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23080/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rationale for this regimen is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    penetration into the CSF starts at a high level in the presence of bacterial meningitis and that impairment in penetration to a level that will reduce efficacy is not likely in the first few days before susceptibility studies are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Begin with a regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      pending studies of susceptibility. A potential problem with routine rifampin therapy is the induction of hepatic CYP isoenzymes, thereby increasing the metabolism of a variety of drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link&amp;anchor=H11#H11\">",
"       \"Rifampin and other rifamycins\", section on 'Drug interactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dosing of the agents in these regimens is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tuberculous meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy may also be beneficial in selected adults and children with tuberculous meningitis. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link&amp;anchor=H30#H30\">",
"     \"Central nervous system tuberculosis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=see_link\">",
"       \"Patient information: Bacterial meningitis (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early intravenous administration of glucocorticoids (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) has been evaluated as adjuvant therapy in an attempt to diminish the rate of hearing loss and other neurologic complications as well as mortality in selected patients with bacterial meningitis. The efficacy of dexamethasone therapy has been reported to vary in developed and developing countries. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When indicated,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      is given 15 to 20 minutes before or at the time of antibiotic administration. Two dose regimens are recommended: 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every six hours for four days in the developed world, based upon the Infectious Diseases Society of America guidelines, and 0.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours for four days in the developing world, based upon the Vietnamese trial. Adjunctive dexamethasone should",
"      <strong>",
"       not",
"      </strong>",
"      be given to adults who have already received antimicrobial therapy because it is unlikely to improve patient outcomes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Therapeutic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults in the developed world with suspected or proven acute pneumococcal meningitis, we recommend administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Dexamethasone should only be continued if the CSF Gram stain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the CSF or blood cultures reveal Streptococcus pneumoniae. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'In developed regions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Developed regions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In areas of the developing world where there is a high prevalence of HIV infection, poor nutrition, and significant delays in clinical presentation, such as some regions of Africa, it is unlikely that the use of adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      will be of benefit. Thus, for adults in such regions with known or suspected bacterial meningitis, we recommend not administering dexamethasone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In other regions of the developing world, we suggest administering dexamethasone in patients who have bacterial meningitis confirmed by Gram stain or a rapid diagnostic test (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). It is also reasonable to empirically administer adjunctive dexamethasone in patients in whom there is a strong clinical suspicion for acute bacterial meningitis until microbiologic results are available. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'In developing regions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Developing regions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with known or suspected pneumococcal meningitis who are treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      to the standard antibiotic regimen (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ) if susceptibility studies show intermediate susceptibility (MIC &ge;2",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      to ceftriaxone and cefotaxime (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A reasonable alternative is to initiate rifampin and then discontinue it if the isolate is susceptible to the cephalosporin. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotic regimens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/1\">",
"      Pfister HW, Feiden W, Einh&auml;upl KM. Spectrum of complications during bacterial meningitis in adults. Results of a prospective clinical study. Arch Neurol 1993; 50:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/2\">",
"      Bhatt SM, Lauretano A, Cabellos C, et al. Progression of hearing loss in experimental pneumococcal meningitis: correlation with cerebrospinal fluid cytochemistry. J Infect Dis 1993; 167:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/3\">",
"      Freyer D, Manz R, Ziegenhorn A, et al. Cerebral endothelial cells release TNF-alpha after stimulation with cell walls of Streptococcus pneumoniae and regulate inducible nitric oxide synthase and ICAM-1 expression via autocrine loops. J Immunol 1999; 163:4308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/4\">",
"      Lutsar I, Friedland IR, Jafri HS, et al. Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. J Antimicrob Chemother 2003; 52:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/5\">",
"      van Furth AM, Roord JJ, van Furth R. Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect Immun 1996; 64:4883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/6\">",
"      S&aacute;ez-Llorens X, Jafari HS, Severien C, et al. Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal antibodies and dexamethasone in experimental Haemophilus meningitis. J Clin Invest 1991; 88:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/7\">",
"      Mai NT, Tuan TV, Wolbers M, et al. Immunological and biochemical correlates of adjunctive dexamethasone in Vietnamese adults with bacterial meningitis. Clin Infect Dis 2009; 49:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/8\">",
"      de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/9\">",
"      van de Beek D, de Gans J. Dexamethasone and pneumococcal meningitis. Ann Intern Med 2004; 141:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/10\">",
"      Weisfelt M, Hoogman M, van de Beek D, et al. Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann Neurol 2006; 60:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/11\">",
"      Brouwer MC, Heckenberg SG, de Gans J, et al. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 2010; 75:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/12\">",
"      Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007; 357:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/13\">",
"      Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med 2007; 357:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/14\">",
"      van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007; :CD004405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/15\">",
"      van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis 2004; 4:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/16\">",
"      van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010; 9:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/17\">",
"      Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010; :CD004405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/18\">",
"      Par&iacute;s MM, Hickey SM, Uscher MI, et al. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994; 38:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/19\">",
"      Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 2007; 44:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/20\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/21\">",
"      Viladrich PF, Gudiol F, Li&ntilde;ares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991; 35:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/22\">",
"      Chaudhuri A. Adjunctive dexamethasone treatment in acute bacterial meningitis. Lancet Neurol 2004; 3:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/23\">",
"      van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23080/abstract/24\">",
"      Greenwood BM. Corticosteroids for acute bacterial meningitis. N Engl J Med 2007; 357:2507.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1299 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23080=[""].join("\n");
var outline_f22_34_23080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94225221\">",
"      COMPLICATIONS OF BACTERIAL MENINGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94225420\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      In developed regions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      In developing regions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1326228962\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect on antibiotic regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THERAPEUTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Developed regions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Developing regions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotic regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tuberculous meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1299|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=related_link\">",
"      Neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_34_23081="Sick sinus syndrome tutorial";
var content_f22_34_23081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1050px;\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Sick sinus syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tracing of sick sinus syndrome (tachycardia-bradycardia syndrome). The initial three beats show atrial fibrillation (AF) which terminates abruptly and is followed after a long offset pause by a junctional escape beat (J) and then a sinus beat (S).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23081=[""].join("\n");
var outline_f22_34_23081=null;
var title_f22_34_23082="Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications";
var content_f22_34_23082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23082/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23082/contributors\">",
"     Kevin R Krull, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23082/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/34/23082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/34/23082/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/34/23082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2007901217\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD) is a disorder that manifests in childhood with symptoms of hyperactivity, impulsivity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inattention. The symptoms affect cognitive, academic, behavioral, emotional, and social functioning (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review focuses on the treatment of ADHD in children and adolescents with medications. The pharmacology of the drugs used to treat ADHD in children and adolescents, the epidemiology, pathogenesis, diagnosis, and prognosis of ADHD in children and adolescents and ADHD in adults are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link\">",
"       \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link\">",
"       \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=see_link\">",
"       \"Adult attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898665\">",
"    <span class=\"h1\">",
"     DECISION TO USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest medications combined with",
"    <span class=\"nowrap\">",
"     behavioral/psychologic",
"    </span>",
"    interventions for most school-aged children (&ge;6 years) and adolescents who meet diagnostic criteria for ADHD (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. We also suggest medications as an adjunct to behavioral interventions for preschool children (4 through 5 years) who meet diagnostic criteria for ADHD and fail to respond to behavioral interventions alone. However, the values and preferences of the patient and family are critical factors in deciding whether or not to initiate medication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/2\">",
"     2",
"    </a>",
"    ]. The decision of families who choose to decline medication must be respected. Comorbid conditions must be taken into account when selecting a specific treatment approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898672\">",
"    <span class=\"h1\">",
"     PREREQUISITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain criteria should be met before pharmacotherapy is initiated (",
"    <a class=\"graphic graphic_table graphicRef66213 \" href=\"UTD.htm?6/44/6860\">",
"     table 2",
"    </a>",
"    ). In addition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A comprehensive, cardiovascular-focused patient history, family history, and physical examination should be completed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link&amp;anchor=H10#H10\">",
"       \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\", section on 'Recommended approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The child&rsquo;s height, weight, blood pressure, and heart rate should be measured.",
"     </li>",
"     <li>",
"      A pretreatment baseline should be established for common side effects associated with pharmacotherapy for ADHD (eg, appetite, sleep pattern, headaches, abdominal pain).",
"     </li>",
"     <li>",
"      Adolescent patients should be assessed for substance use or abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"       6",
"      </a>",
"      ]. Those with signs and symptoms of substance abuse should undergo evaluation and treatment for addiction before treatment for ADHD (if possible) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contraindications to specific medications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898679\">",
"    <span class=\"h1\">",
"     PRETREATMENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiation of medication for ADHD, it is important for the clinician to schedule a visit specifically to discuss treatment with medications. Topics to be addressed at this visit include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An explanation (to the patient) that the medication is being prescribed by the clinician to help the patient with self-control and ability to focus",
"     </li>",
"     <li>",
"      An explanation of the benefits and potential risks of medication, emphasizing the uncertainty about a causal association between serious cardiovascular risks (including sudden unexpected death) and stimulant medications for children with cardiac symptoms or a positive family history of heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/10\">",
"       10",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link\">",
"       \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link\">",
"       \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An explanation of the process and expected length of time (ie, one to three months) involved in determining the best medication, dose, and frequency of administration; this includes (see",
"      <a class=\"local\" href=\"#H2007898721\">",
"       'Dose titration'",
"      </a>",
"      below):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The frequency of follow-up",
"     </li>",
"     <li>",
"      The information that will be needed at follow-up visits or phone calls",
"     </li>",
"     <li>",
"      Behaviors that the family should monitor and report",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry have developed a",
"    <a class=\"external\" href=\"file://www.parentsmedguide.org/pmg_adhd.html\">",
"     Medication guide for ADHD",
"    </a>",
"    to help educate families about the medications used to treat ADHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulant adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898686\">",
"    <span class=\"h1\">",
"     CHOICE OF AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the clinician and patient or parents agree to a trial of medication for ADHD in a school-aged child or adolescent, we suggest a stimulant as the first-line agent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/2,3,11\">",
"     2,3,11",
"    </a>",
"    ]. However, the preferences of the patient and family must be taken into consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    is an alternative. Other medications (eg, alpha-2-adrenergic agonists) usually are used when children respond poorly to a trial of stimulants or atomoxetine, have unacceptable side effects, or have significant coexisting conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898693\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of the initial medication depends upon a number of factors, including (",
"    <a class=\"graphic graphic_table graphicRef80151 \" href=\"UTD.htm?24/32/25101\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3-6,12\">",
"     3-6,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The duration of desired coverage (completion of homework or driving may require coverage into the evening)",
"     </li>",
"     <li>",
"      The ability of the child to swallow pills or capsules",
"     </li>",
"     <li>",
"      The time of day when the target symptoms occur",
"     </li>",
"     <li>",
"      The desire to avoid administration at school",
"     </li>",
"     <li>",
"      Coexisting tic disorder (avoidance of stimulants or use of alpha-2 adrenergic agonists may be warranted)",
"     </li>",
"     <li>",
"      Coexisting emotional or behavioral condition (an alpha-2-adrenergic agonist may be useful for patients who are overaroused, easily frustrated, highly active, or aggressive) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Potential adverse effects",
"     </li>",
"     <li>",
"      History of substance abuse in patient or household member: avoid stimulants or use stimulants with less potential for abuse (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/14/37094?source=see_link\">",
"       lisdexamfetamine",
"      </a>",
"      , osmotic-release preparation,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      patch) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H2#H2\">",
"       \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulants'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Preference of the",
"      <span class=\"nowrap\">",
"       child/adolescent",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      <span class=\"nowrap\">",
"       parent/guardian",
"      </span>",
"     </li>",
"     <li>",
"      Expense (in general, short acting stimulants are least expensive; among long-acting stimulants, pulse formulations are less expensive than bead preparations, osmotic-release preparations, and the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      patch; generic drugs are less expensive than brand-names, but not available for all formulations) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/13\">",
"       13",
"      </a>",
"      ]; generic medications may be used as long as they are systematically titrated (see",
"      <a class=\"local\" href=\"#H2007898721\">",
"       'Dose titration'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898700\">",
"    <span class=\"h2\">",
"     Stimulants versus other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the clinician and patient or parents agree to a trial of medication for ADHD in a school-aged child or adolescent (&ge;6 years), we suggest a stimulant as the first-line agent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"     6",
"    </a>",
"    ]. Stimulants are preferred to other medications because stimulants have a rapid onset of action and long record of safety and efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/4,5,13-18\">",
"     4,5,13-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    may be more appropriate than stimulants for patients with a history of illicit substance use or family members with a history of illicit substance use, concern about abuse or diversion, or a strong family preference against stimulant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,6,12\">",
"     3,6,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alpha-2-adrenergic agonists usually are used when children respond poorly to a trial of stimulants or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , have unacceptable side effects, or have significant coexisting conditions.",
"   </p>",
"   <p>",
"    In randomized trials, systematic reviews, and meta-analyses, stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/15,19-23\">",
"     15,19-23",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/24-34\">",
"     24-34",
"    </a>",
"    ], and alpha-2-adrenergic agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/35-38\">",
"     35-38",
"    </a>",
"    ] are more effective than placebo in reducing the core symptoms of ADHD. However, stimulants typically have a slightly larger treatment effect size (standardized mean difference) than nonstimulants (approximately 1.0 versus approximately 0.7 for both atomoxetine and alpha-2-adrenergic agonists) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/2,3,35,39-41\">",
"     2,3,35,39-41",
"    </a>",
"    ]. The standardized mean difference describes the extent to which the performance in the treatment group differed from that in the control group; by consensus, differences of 0.2, 0.5, and 0.8 are considered small, moderate, and large, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In open-label and blinded randomized trials comparing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , methylphenidate was more effective than or as effective as atomoxetine in reducing target",
"    <span class=\"nowrap\">",
"     symptoms/behaviors",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/39,43-48\">",
"     39,43-48",
"    </a>",
"    ]. Most of these trials were sponsored, at least in part, by the stimulant manufacturers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response rate to a specific stimulant (ie, reduction in hyperactivity or increase in attention as rated by parents, teachers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    research raters) is approximately 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/19,50,51\">",
"     19,50,51",
"    </a>",
"    ]. At least 80 percent of school-age children and adolescents will respond to one of the stimulants if the stimulants are tried in a systematic way.",
"   </p>",
"   <p>",
"    In addition to improvement in core symptoms of ADHD, treatment with stimulants also improves parent-child interactions, aggressive behavior, and academic productivity and accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The effect on academic performance is less strong [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulant medications do not significantly affect learning problems, reduced social skills, oppositional behavior, or emotional problems that are secondary to or coexist with ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/54\">",
"     54",
"    </a>",
"    ]. However, stimulant medications may facilitate the psychologic or behavioral treatment of these problems by controlling the core symptoms of ADHD. In addition, the use of stimulant medications may improve self-esteem in children with ADHD and comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few controlled studies of long-term therapy for ADHD; however, ADHD symptoms appear to improve with time regardless of treatment modality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/23,56\">",
"     23,56",
"    </a>",
"    ]. A systematic review found few good quality studies assessing the long-term effectiveness of treatment with stimulants or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , but concluded that medications continue to be effective and well-tolerated over at least 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/42\">",
"     42",
"    </a>",
"    ]. In one study, participants in a controlled trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    were followed over five years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients who continued on stimulants for five years had fewer teacher-reported ADHD symptoms than those off medication and those who did not adhere to stimulant therapy. The most common adverse effect in the group that continued stimulants for five years was appetite suppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898707\">",
"    <span class=\"h2\">",
"     Choosing among stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual preferences of the clinician and family determine the choice of the initial stimulant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. In choosing among the various stimulants, duration of action is a primary consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/16\">",
"     16",
"    </a>",
"    ]. Another consideration is whether or not the child can swallow pills (since some formulations cannot be crushed, split, or opened) (",
"    <a class=\"graphic graphic_table graphicRef80151 \" href=\"UTD.htm?24/32/25101\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In most systematic reviews,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/9/17559?source=see_link\">",
"     dexmethylphenidate",
"    </a>",
"    , and amphetamines appear to be equally effective and to have similar adverse effect profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/22,58,59\">",
"     22,58,59",
"    </a>",
"    ]. However, one meta-analysis found amphetamines to be moderately more efficacious than methylphenidate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Short-acting forms of medication (",
"    <a class=\"graphic graphic_table graphicRef81815 \" href=\"UTD.htm?38/59/39869\">",
"     table 4A",
"    </a>",
"    ) are often used as the initial treatment in children &lt;6 years, who are more sensitive to dose-dependent adverse effects and should be started at low doses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. Long-acting formulations generally are not available at doses small enough for young children. Short-acting forms also may be used to determine the optimal daily dose before switching to a comparable long-acting agent (",
"    <a class=\"graphic graphic_table graphicRef77580 \" href=\"UTD.htm?33/21/34142\">",
"     table 4B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/61\">",
"     61",
"    </a>",
"    ]. However, in children older than six years, a longer-acting preparation may be used initially, starting at the lowest dose and titrating up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2007898721\">",
"     'Dose titration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Intermediate or long-acting preparations generally are indicated for children who require a duration of action longer than four hours or in whom the administration of medication every four hours is inconvenient, stigmatizing, or impossible [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,6,18,62\">",
"     3,6,18,62",
"    </a>",
"    ]. Long-acting medications may improve adherence and are potentially less likely to be misused or diverted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/18,63\">",
"     18,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A combination of a long-acting and late-afternoon short-acting medication may be necessary to provide adequate coverage in the evening hours for homework completion or driving [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898714\">",
"    <span class=\"h2\">",
"     Preschool children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication may be helpful for preschool children who have failed an adequate trial of behavior therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ]. When the clinician and parents agree that medication is warranted for a preschool child, we suggest",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    rather than amphetamines or nonstimulant medication.",
"   </p>",
"   <p>",
"    A systematic review found only one good quality study of stimulant medication in preschool children with ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/42\">",
"     42",
"    </a>",
"    ]. In the multicenter Preschool ADHD Treatment Study (PATS), treatment with immediate release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    improved ADHD symptoms in children (3 to 5.5 years) with ADHD who were unresponsive to psychosocial interventions (effect size [standardized mean difference] 0.4 to 0.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/64\">",
"     64",
"    </a>",
"    ]. However, the effect size was smaller than that generally seen in older children (approximately 1.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,40\">",
"     3,40",
"    </a>",
"    ]. The standardized mean difference describes the extent to which the performance in the treatment group differed from that in the control group; by consensus, differences of 0.2, 0.5, and 0.8 are considered small, moderate, and large, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/42\">",
"     42",
"    </a>",
"    ]. In a subsequent trial randomized trial,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    improved core symptoms of ADHD in preschool children, but did not improve clinical function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/32\">",
"     32",
"    </a>",
"    ]. Controlled studies comparing methylphenidate with other medications for preschool children are lacking.",
"   </p>",
"   <p>",
"    Initiation and titration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    for preschool children is discussed below. (See",
"    <a class=\"local\" href=\"#H2165707\">",
"     'Dose titration for preschool children'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898721\">",
"    <span class=\"h1\">",
"     DOSE TITRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy for ADHD has three stages: titration, maintenance, and termination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/8\">",
"     8",
"    </a>",
"    ]. During the titration stage, the optimal dose and frequency of medication are determined. The optimal dose is the dose at which target outcomes are achieved with minimal side effects. The titration phase lasts from one to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/8\">",
"     8",
"    </a>",
"    ]. It requires close monitoring (usually weekly) by the clinician, some of which can be done by phone.",
"   </p>",
"   <p>",
"    It is helpful to start ADHD medication on a weekend day so that parents can watch for adverse effects with the first doses. It is also helpful to write prescriptions so that the pharmacy will provide a separate bottle of medication, with appropriate instructions, for administration at school (if administration at school is necessary). Children should not be allowed to administer their own medication. Adolescents may administer their own medication. However, it is important for parents to monitor adherence (through pill counting and observation of behavior). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29368442\">",
"    <span class=\"h2\">",
"     Titration of stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose-response relationship for stimulant medication varies by child (perhaps related to genetic polymorphisms) and within the child may vary by domain of function or target symptoms of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Individual differences in metabolism preclude weight-based dosing of stimulant medications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/8\">",
"     8",
"    </a>",
"    ]. The optimal regimen is determined by changes in core symptoms and occurrence of side effects.",
"   </p>",
"   <p>",
"    Stimulant medications usually are started at the lowest dose that may produce an effect and increased gradually (every three to seven days) until core symptoms improve by 40 to 50 percent compared with baseline or adverse effects become unacceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6,8,18\">",
"     6,8,18",
"    </a>",
"    ]. The maximum daily dose for stimulant medications is provided in the tables. (",
"    <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"     table 4A-B",
"    </a>",
"    ). However, doses exceeding the recommended maximum doses may be necessary for adult-sized adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a therapeutic dose, the effects of stimulant medications on core symptoms usually are apparent 30 to 40 minutes after administration and continue for the expected duration of action [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Administration with a high fat meal may delay the onset and increase peak concentrations of some formulations (eg, Metadate CD&reg;, Methylin&reg; chewable tablets or oral solutions, Adderall XR&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     \"Methylphenidate: Pediatric drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"     \"Dextroamphetamine: Pediatric drug information\"",
"    </a>",
"    .) Appetite suppression may be another indicator of treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/8\">",
"     8",
"    </a>",
"    ]. Inadequate dose may be indicated by a shorter than expected duration of action.",
"   </p>",
"   <p>",
"    The decision regarding the frequency of stimulant medication (both times per day and days per week) is based upon the type of ADHD and the domains of function in which improvement is desired. As an example, a child with the predominantly inattentive type of ADHD may need medication only on school days, whereas a child who has difficulty with peer relationships may need medication every day. Children who participate in after-school sports or activities on certain days of the week may require longer-acting preparations or more frequent dosing on those days. The full scope dosing schedules have not been studied in controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2165707\">",
"    <span class=\"h3\">",
"     Dose titration for preschool children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    is slower in preschool children than in older children and adolescents. Preschool children usually are started at a lower dose that is increased in smaller increments. In the Preschool ADHD Treatment Study (PATS), preschool children were started on methylphenidate 1.25 mg orally twice per day and increased to 7.5 mg orally three times per day during the course of one week [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/64\">",
"     64",
"    </a>",
"    ]. The mean optimal total daily dose was 14.2 &plusmn; 8.1",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2152372\">",
"    <span class=\"h2\">",
"     Titration of atomoxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Titration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    depends upon the child&rsquo;s weight:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children and adolescents weighing &le;70 kg should be started at a dose of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for a minimum of three days and then titrated up to a daily dose of approximately 1.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in either one or two daily doses; the maximum daily dose should not exceed 1.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 100 mg, whichever is less.",
"     </li>",
"     <li>",
"      Patients who weigh more than 70 kg should be started at a dose of 40 mg for a minimum of three days, followed by an increase to approximately 80 mg; after two to four weeks, the dose may be increased to a maximum of 100 mg if additional benefit is needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    may not be apparent for one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2165166\">",
"    <span class=\"h2\">",
"     Monitoring response and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the titration stage, the child's core symptoms and adverse effects should be assessed weekly and the medication dose adjusted as indicated (",
"    <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"     table 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/61,73-75\">",
"     61,73-75",
"    </a>",
"    ]. Core symptoms and adverse effects can be monitored through parent and teacher feedback",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ADHD rating scales (",
"    <a class=\"graphic graphic_table graphicRef81675 \" href=\"UTD.htm?21/27/21949\">",
"     table 5",
"    </a>",
"    ) (via telephone, fax, or secure electronic system) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients generally are seen at least once per month to monitor weight, height, heart rate, and blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,6,73\">",
"     3,6,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulant adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Teacher feedback is essential. Many parents choose a medication regimen for their child that has maximal effects during the school day. In such cases, parents may not be in a position to observe medication effects on core ADHD symptom and reports from the parents alone are not sufficient to make a determination of treatment failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2166605\">",
"    <span class=\"h3\">",
"     Managing stimulant adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;When children or adolescents who are being treated with stimulant medications develop adverse effects, it is important to determine the timing of the effect in relation to medication administration and whether the effect is related to a coexisting disorder or environmental stressor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/8,76\">",
"     8,76",
"    </a>",
"    ]. Mild adverse effects may resolve with time or can be addressed by adjusting the dose, time of administration, or formulation of stimulant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,6,73\">",
"     3,6,73",
"    </a>",
"    ]. Tips for initial management of common adverse effects of stimulant medications are provided below [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Decreased appetite",
"      </strong>",
"      &ndash; Administer the medication at or after a meal; encourage the child to eat nutrient dense foods before those with &ldquo;empty calories&rdquo;; offer food that the child likes for the noon meal, which is often affected [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6,8,72,76\">",
"       6,8,72,76",
"      </a>",
"      ]. When making these changes, an important caveat is that meals with high fat content may delay the onset and increase peak concentrations of some formulations (eg, Metadate CD&reg;, Methylin&reg; chewable tablets or oral solutions, Adderall XR&reg;). (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       \"Methylphenidate: Pediatric drug information\"",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=see_link\">",
"       \"Dextroamphetamine: Pediatric drug information\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      <strong>",
"       Poor growth",
"      </strong>",
"      &ndash; Drug holidays may be beneficial for children in whom stimulant therapy is associated with a growth trajectory that crosses two major percentiles (ie, the 5",
"      <sup>",
"       th",
"      </sup>",
"      , 10",
"      <sup>",
"       th",
"      </sup>",
"      , 25",
"      <sup>",
"       th",
"      </sup>",
"      , 50",
"      <sup>",
"       th",
"      </sup>",
"      , 75",
"      <sup>",
"       th",
"      </sup>",
"      , 90",
"      <sup>",
"       th",
"      </sup>",
"      , and 95",
"      <sup>",
"       th",
"      </sup>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3\">",
"       3",
"      </a>",
"      ]. Drug holidays should only be undertaken if they can be tolerated without marked impairment in functioning. (See",
"      <a class=\"local\" href=\"#H2007898756\">",
"       'Drug holidays'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Dizziness",
"      </strong>",
"      &ndash; Monitor blood pressure and pulse; ensure adequate fluid intake; if associated only with peak effect, try a longer-acting preparation (",
"      <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"       table 4A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Insomnia/nightmares",
"       </strong>",
"      </span>",
"      &ndash; Establish a bedtime routine and good sleep hygiene habits; omit or reduce the last dose of the day or, if using a long-acting preparation, change to a short-acting preparation (",
"      <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"       table 4A-B",
"      </a>",
"      ) or administer earlier in the day [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/16,76,77\">",
"       16,76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Mood lability",
"      </strong>",
"      &ndash; If mood lability occurs at the time of peak concentration, try reducing the dose or switching to a longer acting preparation; irritability, sadness, and increased activity as the medication wears off is particularly common when short-acting medication is used on a morning and noon twice-a-day schedule&mdash;try adding an afternoon dose or switching to long-acting form; referral for coexisting mood disorder or anxiety disorder may be warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <strong>",
"       Rebound",
"      </strong>",
"      &ndash; &ldquo;Rebound&rdquo; refers to symptoms or adverse effects that occur as the medication is wearing off; rebound effects may improve by stepping down the dose at the end of the day (by increasing the dose of the long-acting agent administered in the morning or adding a smaller dose of short-acting medication at the end of the day) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,76\">",
"       3,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Tics",
"      </strong>",
"      &ndash; Conduct a drug trial at different doses, including no medication, to be sure that tics are drug-related; if tics abate on no medication, reconsider the risks and benefits of treatment with the patient and family [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Psychosis",
"      </strong>",
"      &ndash; If children taking stimulant medications develop psychotic symptoms (eg, suicidality, hallucinations, or increased aggression), verify that the dose is appropriate and that the medication is being administered as prescribed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/76\">",
"       76",
"      </a>",
"      ]. If so, discontinue the stimulant; stimulant medications can be discontinued abruptly, without tapering. Referral to a qualified mental health specialist or psychopharmacologist may be warranted to assess for bipolar disorder or a thought disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Diversion and misuse",
"      </strong>",
"      &ndash; It is important for clinicians to monitor symptoms and prescription refills for evidence of misuse or diversion of ADHD medication [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"       6",
"      </a>",
"      ]. Stimulant diversion and misuse can be prevented, to some extent, by prescribing long-acting stimulants (",
"      <a class=\"graphic graphic_table graphicRef77580 \" href=\"UTD.htm?33/21/34142\">",
"       table 4B",
"      </a>",
"      ) with less potential for abuse, and by keeping track of prescription dates [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/16,63\">",
"       16,63",
"      </a>",
"      ]. It is also helpful to have an open discussion about stimulant diversion and misuse with patients and parents so that students can be prepared if they are approached by peers to sell or misuse medications and so that parents can remain vigilant in monitoring medications [",
"      <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2165451\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure is defined by lack of satisfactory improvement in core symptoms of ADHD at the maximum dose or the occurrence of intolerable adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6,78\">",
"     6,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to differentiate lack of response from &ldquo;rebound&rdquo; effects as the medication wears off [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/8\">",
"     8",
"    </a>",
"    ]. With lack of response there is no improvement in core symptoms; with &ldquo;rebound&rdquo;, there is an initial improvement in core symptoms, but near the end of the expected duration of action, there may be a recurrence or worsening of symptoms. (See",
"    <a class=\"local\" href=\"#H2166605\">",
"     'Managing stimulant adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children who fail to have improvement in core symptoms at the maximum recommended dose (",
"    <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"     table 4A-B",
"    </a>",
"    ) or who have intolerable side effects on one type of stimulant medication can be tried on the other type of stimulant medication (with a similar titration process) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/23\">",
"     23",
"    </a>",
"    ]. At least one-half of children who do not respond to one type of stimulant will respond to the other [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6,23,41\">",
"     6,23,41",
"    </a>",
"    ]. Side effects may occur with one type of stimulant but not another [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/41,79\">",
"     41,79",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     Atomoxetine",
"    </a>",
"    or an alpha-2 adrenergic may be a better choice than a second stimulant for children who have onset or exacerbation of tics with the first stimulant. Children who do not respond to a second stimulant may respond to nonstimulant medications or the addition of extended release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/11,80\">",
"     11,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Review of the initial presentation and diagnosis is warranted for children who do not respond to a second stimulant at the maximum dose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/16\">",
"     16",
"    </a>",
"    ]. The following possibilities must be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of adherence to the medication regimen",
"     </li>",
"     <li>",
"      The possibility of medication diversion (eg, giving or selling the medication to others)",
"     </li>",
"     <li>",
"      Whether the expectations are realistic",
"     </li>",
"     <li>",
"      Whether there is a comorbid psychiatric diagnosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H13#H13\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Differential diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898742\">",
"    <span class=\"h2\">",
"     Changing from one medication to another",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changing from one medication is warranted for children who do not have improvement in core symptoms at the maximum recommended dose or who have intolerable side effects. Dosing guidelines for switching from one stimulant to another are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef61007 \" href=\"UTD.htm?5/58/6062\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When switching from a stimulant to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , stimulant medication should be continued for the first few weeks (unless stimulant treatment was associated with concerning side effects) to allow atomoxetine to reach full effect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast, if switching from atomoxetine to stimulants for lack of response, atomoxetine can be stopped abruptly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898749\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance stage begins once the optimal dose and frequency of medication have been determined. During the maintenance stage, regular monitoring is necessary to review progress, adjust the dose if necessary, monitor adverse effects of therapy, and review the child's understanding of the medication as he or she matures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,61\">",
"     3,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of follow-up during the maintenance phase may range from every three to six months depending upon adherence, coexisting conditions, and the persistence of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"     6",
"    </a>",
"    ]. More frequent visits generally are necessary for children with coexisting conditions. In addition to office visits every three to six months, telephone monitoring should occur at the time of medication refill requests. Communication with teachers or other school personnel can be tailored to individual patient and family needs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H2007891978#H2007891978\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Care coordination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The child's height, weight, blood pressure, and pulse should continue to be monitored during the maintenance stage. Additional adverse effects must be monitored closely because stimulant medication may be used for many years. Structured monitoring can be performed with the use of a side effects profile. One such symptom rating scale for evaluating side effects of medications is included in the National Initiative for Children&rsquo;s Healthcare Quality sample management plans (",
"    <a class=\"external\" href=\"file://www.nichq.org/adhd_tools.html\">",
"     www.nichq.org/adhd.html",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulant adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H21#H21\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Atomoxetine adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintenance doses typically are similar to the doses demonstrating optimal efficacy during the titration period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/41,81,82\">",
"     41,81,82",
"    </a>",
"    ]. However, medication adjustments may be necessary to accommodate changes in the child's lifestyle or activities. Long-acting medications may interfere with sleep onset in adolescents who sleep later on weekend mornings than they do during the week [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/16\">",
"     16",
"    </a>",
"    ]. In such patients, the use of a shorter-acting preparation on weekend days may be beneficial. When adjustments to the maintenance dose are necessary, they should not exceed the smallest available unit for the specific medication (",
"    <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"     table 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Adherence to the treatment regimen can be monitored by documenting the dates of prescription refills. Parents may overestimate adherence to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898756\">",
"    <span class=\"h2\">",
"     Drug holidays",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Drug holidays&rdquo; (ie, discontinuation of stimulant medication on weekends or during the summer) are not routinely recommended because ADHD is a chronic and pervasive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/16\">",
"     16",
"    </a>",
"    ]. Decisions about drug holidays must be made on a case by case basis. As an example, a child with the predominantly inattentive type of ADHD may need medication only on school days. Drug holidays are not an option for children who are taking",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    or alpha-2-adrenergic agonists (eg, extended release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/53/42839?source=see_link\">",
"     guanfacine",
"    </a>",
"    , extended release",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    ) because of the long half-life of these medications.",
"   </p>",
"   <p>",
"    Drug holidays, if they can be tolerated without marked impairment of functioning, may be beneficial for children in whom stimulant therapy is associated with an aberrant growth trajectory (eg, a growth trajectory that crosses two major percentiles; the major percentiles are the 5",
"    <sup>",
"     th",
"    </sup>",
"    , 10",
"    <sup>",
"     th",
"    </sup>",
"    , 25",
"    <sup>",
"     th",
"    </sup>",
"    , 50",
"    <sup>",
"     th",
"    </sup>",
"    , 75",
"    <sup>",
"     th",
"    </sup>",
"    , 90",
"    <sup>",
"     th",
"    </sup>",
"    , and 95",
"    <sup>",
"     th",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulant adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of a weekend drug holiday were evaluated in a controlled study in which 40 children and adolescents were randomly assigned to receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    twice per day, seven days per week or twice per day on weekdays and placebo on weekends [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/84\">",
"     84",
"    </a>",
"    ]. There were no differences between groups on Monday teacher ratings or weekend parent ratings, but those in the drug holiday group had significantly less insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007898763\">",
"    <span class=\"h1\">",
"     TERMINATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of pharmacologic therapy is highly individualized. Ongoing evaluation of the risks and benefits of medication is necessary for each patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. At the 36-month follow-up of participants in a multicenter randomized trial of ADHD treatments (medication;",
"    <span class=\"nowrap\">",
"     behavioral/psychological",
"    </span>",
"    therapy; combination medication and",
"    <span class=\"nowrap\">",
"     behavioral/psychological",
"    </span>",
"    therapy; and community care), the treatment groups had similar clinical and functional outcomes (all substantially improved compared with baseline) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, after several years of medication, it is reasonable to offer children and adolescents who have had stable improvement in ADHD symptoms and target behaviors a trial off of medication to determine whether medication is still necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"     6",
"    </a>",
"    ]. Such a trial is should be undertaken with close monitoring of core symptoms and function at home, school, and in the community.",
"   </p>",
"   <p>",
"    To prevent unsupervised termination of medication, the procedures for a trial period off medicine should be discussed routinely with patients. Regular assessment and monitoring of behavior through formal ratings appears to decrease the rate of unsupervised termination of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/85\">",
"     85",
"    </a>",
"    ]. Although controlled studies are lacking, occasional trials off medication may assist in determining whether continuation of medication is necessary. If conducted, such trials should be timed so as not to interfere with academic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vocational efforts. Because long-term side effects and drug dependence do not occur with stimulant medications or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     atomoxetine",
"    </a>",
"    , they can be discontinued by stopping all doses at once [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/65,85,86\">",
"     65,85,86",
"    </a>",
"    ]. However, the discontinuation of alpha-2-adrenergic agonists and tricyclic antidepressants should follow established guidelines (ie, tapering off over several weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/34/23082/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/42/3746?source=see_link\">",
"       \"Patient information: Medicines for attention deficit hyperactivity disorder (ADHD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2007901225\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest medications (with or without",
"      <span class=\"nowrap\">",
"       behavioral/psychologic",
"      </span>",
"      interventions) for school-aged children (&ge;6 years) and adolescents who meet diagnostic criteria for attention deficit hyperactivity disorder (ADHD) (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We also suggest medications as an adjunct to behavioral interventions for preschool children (4 through 5 years) who meet diagnostic criteria for ADHD and fail to respond to behavioral interventions alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the values and preferences of the patient and family are critical factors in deciding whether or not to initiate medication. (See",
"      <a class=\"local\" href=\"#H2007898665\">",
"       'Decision to use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain criteria should be met before pharmacotherapy is initiated (",
"      <a class=\"graphic graphic_table graphicRef66213 \" href=\"UTD.htm?6/44/6860\">",
"       table 2",
"      </a>",
"      ). In addition, a comprehensive, cardiovascular history and examination should be completed; baseline height, weight, blood pressure, and heart rate should be established; and adolescent patients should be assessed for substance use or abuse. In addition, a pretreatment baseline should be established for common side effects (eg, appetite, sleep, headaches, abdominal pain, etc). (See",
"      <a class=\"local\" href=\"#H2007898672\">",
"       'Prerequisites'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link\">",
"       \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pretreatment education includes an explanation of the rationale for medication treatment, the benefits and potential risks of medication, and the process of determining the optimal regimen. (See",
"      <a class=\"local\" href=\"#H2007898679\">",
"       'Pretreatment education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the clinician and patient or parents agree to a trial of medication for ADHD in a school-aged child or adolescent, we suggest a stimulant as the first-line agent (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ); for preschool children we suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       methylphenidate",
"      </a>",
"      rather than amphetamines or nonstimulant drugs (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the preferences of the patient and family must be taken into consideration.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"       Atomoxetine",
"      </a>",
"      is an alternative. Other medications (eg, alpha-2-adrenergic agonists) usually are used when children respond poorly to a trial of stimulants or atomoxetine, have unacceptable side effects, or have significant coexisting conditions. (See",
"      <a class=\"local\" href=\"#H2007898686\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individual preferences of the clinician and family determine the choice of the initial stimulant medication. In choosing among the various stimulants, duration of action is a primary consideration (",
"      <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"       table 4A-B",
"      </a>",
"      ). Another consideration is whether or not the child can swallow pills (",
"      <a class=\"graphic graphic_table graphicRef80151 \" href=\"UTD.htm?24/32/25101\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2007898707\">",
"       'Choosing among stimulants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the titration stage, the optimal dose and frequency of medication are determined. The optimal dose is the dose at which target outcomes are achieved with minimal side effects. The titration stage lasts from one to three months and requires close monitoring of core symptoms, target outcomes, and adverse effects by the clinician. Guidelines for the initial dose and dose advancement are provided in the tables (",
"      <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"       table 4A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2007898721\">",
"       'Dose titration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2165166\">",
"       'Monitoring response and adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment failure is defined by lack of satisfactory improvement in core symptoms of ADHD at the maximum dose (",
"      <a class=\"graphic graphic_table graphicRef81815 graphicRef77580 \" href=\"UTD.htm?42/60/43983\">",
"       table 4A-B",
"      </a>",
"      ) or the occurrence of intolerable adverse effects. Children who fail treatment with one type of stimulant medication can be tried the other (with a similar titration process). Dosing guidelines for switching from one stimulant to another are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef61007 \" href=\"UTD.htm?5/58/6062\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2165451\">",
"       'Treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Review of the initial presentation and diagnosis is warranted for children who do not respond to a second stimulant at the maximum dose. The following possibilities must be considered (see",
"      <a class=\"local\" href=\"#H2165451\">",
"       'Treatment failure'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lack of adherence to the medication regimen",
"     </li>",
"     <li>",
"      The possibility of medication diversion (eg, giving or selling the medication to others)",
"     </li>",
"     <li>",
"      Whether the expectations are realistic",
"     </li>",
"     <li>",
"      Whether there is a comorbid psychiatric diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The maintenance stage begins once the optimal dose and frequency of medication have been determined. Continued monitoring of progress and adverse effects is necessary during the maintenance phase. The frequency of follow-up depends upon adherence, coexisting conditions, and the persistence of symptoms. During the maintenance phase, decisions regarding discontinuation of stimulant medication on weekends or school vacations must be made on a case by case basis. (See",
"      <a class=\"local\" href=\"#H2007898749\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of pharmacologic therapy is highly individualized; ongoing evaluation of the risks and benefits of medication is necessary for each patient. After several years of medication, it is reasonable to offer children and adolescents who have had stable improvement in ADHD symptoms and target behaviors a trial off of medication to determine whether medication is still necessary. Such a trial is should be undertaken with close monitoring of core symptoms and function at home, school, and in the community. (See",
"      <a class=\"local\" href=\"#H2007898763\">",
"       'Termination of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4th, American Psychiatric Association, Washington, DC 2000. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/2\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/3\">",
"      Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. www.nice.org.uk/CG72 (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     Scottish Intercollegiate Guidelines Network. Management of attention deficit and hyperkinetic disorders in children and young people. file://www.sign.ac.uk/guidelines/fulltext/112/index.html (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/6\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/7\">",
"      Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998; 37:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/8\">",
"      Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 2001; 22:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/9\">",
"      American Academy of Child and Adolescent Psychiatry. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry 2009; 48:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/10\">",
"      Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do? Pediatrics 2006; 118:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/11\">",
"      Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/12\">",
"      Harpin VA. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006. Arch Dis Child Educ Pract Ed 2008; 93:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/13\">",
"      Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009; 48:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/14\">",
"      Taylor E, D&ouml;pfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1:I7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/15\">",
"      Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115:e749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/16\">",
"      Schonwald A. Update: attention deficit/hyperactivity disorder in the primary care office. Curr Opin Pediatr 2005; 17:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/17\">",
"      Wigal SB. Efficacy and safety limitations of attention deficit hyperactivity disorder pharmacotherapy in pediatric patients. J Pediatr 2009; 154:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/18\">",
"      Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am 2011; 58:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/19\">",
"      Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001; 165:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/20\">",
"      Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007; 29:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/21\">",
"      Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004; 43:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/22\">",
"      Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999; :i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/23\">",
"      A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/24\">",
"      Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108:E83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/25\">",
"      Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/26\">",
"      Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 2002; 110:e75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/27\">",
"      Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/28\">",
"      Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005; 44:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/29\">",
"      Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/30\">",
"      Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/31\">",
"      Martenyi F, Zavadenko NN, Jarkova NB, et al. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry 2010; 19:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/32\">",
"      Kratochvil CJ, Vaughan BS, Stoner JA, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics 2011; 127:e862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/33\">",
"      Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/34\">",
"      Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007; 194:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/35\">",
"      Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/36\">",
"      Palumbo DR, Sallee FR, Pelham WE Jr, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/37\">",
"      Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121:e73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/38\">",
"      Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/39\">",
"      Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/40\">",
"      Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006; 8:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/41\">",
"      Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35:1304.",
"     </a>",
"    </li>",
"    <li>",
"     Charach A, Dashti B, Carson P, et al. Attention deficit hyperactivity disorder: Effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment. AHRQ Publication No. 12-EHC003, Agency for Healthcare Research and Quality, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/43\">",
"      Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/44\">",
"      Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 2007; 41:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/45\">",
"      Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc 2005; 97:11S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/46\">",
"      Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005; 22:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/47\">",
"      Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/48\">",
"      Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 2011; 11:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/49\">",
"      Atomoxetine (Strattera) revisited. Med Lett Drugs Ther 2004; 46:65.",
"     </a>",
"    </li>",
"    <li>",
"     Miller A, Lee SK, Raina P, et al. A review of therapies for attention deficit hyperactivity disorder. Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1999. file://cadth.ca/en/products/health-technology-assessment/publication/20 (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/51\">",
"      Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2006; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/52\">",
"      Carlson CL, Pelham WE Jr, Milich R, Dixon J. Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol 1992; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/53\">",
"      Floet AM, Scheiner C, Grossman L. Attention-deficit/hyperactivity disorder. Pediatr Rev 2010; 31:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/54\">",
"      Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/55\">",
"      Frankel F, Cantwell DP, Myatt R, Feinberg DT. Do stimulants improve self-esteem in children with ADHD and peer problems? J Child Adolesc Psychopharmacol 1999; 9:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/56\">",
"      Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007; 46:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/57\">",
"      Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004; 43:559.",
"     </a>",
"    </li>",
"    <li>",
"     Lord J, Paisley S. The clinical effectiveness and cost-effectiveness of methylphenidate for hyperactivity in childhood. National Institute for Clinical Excellence, Version 2, London 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/59\">",
"      Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002; 22:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/60\">",
"      Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     Miller KJ, Wender EH. Attention deficit/hyperactivity disorder. In: Primary Pediatric Care, 4th ed, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.756.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/62\">",
"      Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/63\">",
"      Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/64\">",
"      Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/65\">",
"      Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/66\">",
"      Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/67\">",
"      Froehlich TE, Epstein JN, Nick TG, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/68\">",
"      Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/69\">",
"      Tulloch SJ, Zhang Y, McLean A, Wolf KN. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy 2002; 22:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/70\">",
"      Rapport MD, Randall R, Moffitt C. Attention-Deficit/Hyperactivity Disorder and methylphenidate: a dose-response analysis and parent-child comparison of somatic complaints. J Atten Disord 2002; 6:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/71\">",
"      Gonz&aacute;lez MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002; 40:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/72\">",
"      Auiler JF, Liu K, Lynch JM, Gelotte CK. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr Med Res Opin 2002; 18:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/73\">",
"      Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41:26S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/74\">",
"      Cyr M, Brown CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 1998; 56:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/75\">",
"      Hill P, Taylor E. An auditable protocol for treating attention deficit/hyperactivity disorder. Arch Dis Child 2001; 84:404.",
"     </a>",
"    </li>",
"    <li>",
"     Leslie LK, Guevara JP. Attention-deficit/hyperactivity disorder. In: American Academy of Pediatrics Textbook of Pediatric Care, McInerny TK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.1201.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/77\">",
"      Corkum P, Davidson F, Macpherson M. A framework for the assessment and treatment of sleep problems in children with attention-deficit/hyperactivity disorder. Pediatr Clin North Am 2011; 58:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/78\">",
"      Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder: an update. Pediatr Rev 2002; 23:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/79\">",
"      Hale JB, Hoeppner JA, DeWitt MB, et al. Evaluating medication response in ADHD: cognitive, behavioral, and single-subject methodology. J Learn Disabil 1998; 31:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/80\">",
"      Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011; 127:e1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/81\">",
"      Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/82\">",
"      Vitiello B, Severe JB, Greenhill LL, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry 2001; 40:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/83\">",
"      Pappadopulos E, Jensen PS, Chait AR, et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry 2009; 48:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/84\">",
"      Martins S, Tramontina S, Polanczyk G, et al. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 2004; 14:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/85\">",
"      Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2001; 40:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/86\">",
"      Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 2004; 24:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/34/23082/abstract/87\">",
"      Shelton RC. Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy. Prim Care Companion J Clin Psychiatry 2001; 3:168.",
"     </a>",
"    </li>",
"    <li>",
"     Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd edition. American Psychiatric Association, 2010. file://www.psych.org/guidelines/mdd2010 (Accessed on February 21, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16927 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23082=[""].join("\n");
var outline_f22_34_23082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2007901225\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007901217\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898665\">",
"      DECISION TO USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898672\">",
"      PREREQUISITES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898679\">",
"      PRETREATMENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898686\">",
"      CHOICE OF AGENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898693\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898700\">",
"      Stimulants versus other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898707\">",
"      Choosing among stimulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898714\">",
"      Preschool children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898721\">",
"      DOSE TITRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29368442\">",
"      Titration of stimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2165707\">",
"      - Dose titration for preschool children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2152372\">",
"      Titration of atomoxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2165166\">",
"      Monitoring response and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2166605\">",
"      - Managing stimulant adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2165451\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898742\">",
"      Changing from one medication to another",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898749\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898756\">",
"      Drug holidays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007898763\">",
"      TERMINATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2007901225\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16927|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/27/11709\" title=\"table 1\">",
"      DSM-IV-TR criteria for ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/44/6860\" title=\"table 2\">",
"      Initiation ADHD drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/32/25101\" title=\"table 3\">",
"      ADHD drugs comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/59/39869\" title=\"table 4A\">",
"      Immediate release preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/21/34142\" title=\"table 4B\">",
"      Long-acting meds for ADHD in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/27/21949\" title=\"table 5\">",
"      Behavior rating scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/58/6062\" title=\"table 6\">",
"      Approximate dose equivalents stimulants for ADHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=related_link\">",
"      Adult attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=related_link\">",
"      Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/7/6263?source=related_link\">",
"      Dextroamphetamine: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=related_link\">",
"      Methylphenidate: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/42/3746?source=related_link\">",
"      Patient information: Medicines for attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_34_23083="Lung transplant donor criteria";
var content_f22_34_23083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ideal lung transplant donor criteria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Age &lt;55 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABO compatibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clear chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pa0",
"        <sub>",
"         2",
"        </sub>",
"        &gt;300 on Fi0",
"        <sub>",
"         2",
"        </sub>",
"        = 1.0, PEEP - 5cm H",
"        <sub>",
"         2",
"        </sub>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobacco history &lt;20 pack years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of chest trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No evidence of aspiration/sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No prior cardiopulmonary surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sputum gram stain - absence of organisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of purulent secretions at bronchoscopy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Fi0",
"     <sub>",
"      2",
"     </sub>",
"     : fraction of inspired oxygen; Pa0",
"     <sub>",
"      2",
"     </sub>",
"     : partial pressure of arterial oxygen; PEEP: positive end-expiratory pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Bhorade, SM, Vigneswaran, W, McCabe, MA, Garrity, ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000; 19:1199.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23083=[""].join("\n");
var outline_f22_34_23083=null;
var title_f22_34_23084="Early primary tooth loss";
var content_f22_34_23084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with premature primary tooth exfoliation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Oral manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypophosphatasia (OMIM #146300 &amp; #241500)",
"       </td>",
"       <td>",
"        Tooth loss as early as one year of age, minimal soft-tissue inflammation, large dental pulp chambers, variable enamel hypoplasia",
"       </td>",
"       <td>",
"        Decreased alkaline phosphatase, severe cases can have bone manifestations, bowing of legs, short stature",
"       </td>",
"       <td>",
"        Autosomal dominant and recessive forms, mutations in tissue-nonspecific alkaline phosphatase gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papillon Lef&egrave;vre syndrome (OMIM #245000)",
"       </td>",
"       <td>",
"        Tooth loss beginning second to third year of life, marked soft-tissue inflammation, generalized alveolar bone loss",
"       </td>",
"       <td>",
"        Hyperkeratosis of palmar and plantar surfaces",
"       </td>",
"       <td>",
"        Autosomal recessive trait, mutation in cathepsin gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclic neutropenia (OMIM #162800)",
"       </td>",
"       <td>",
"        Severe erythematous gingivitis, can have rapid periodontal breakdown and bone loss",
"       </td>",
"       <td>",
"        Recurrent fevers, malaise, sore throat, anorexia, 21-day periodicity of decreased neutrophils",
"       </td>",
"       <td>",
"        Autosomal dominant trait, defect in neutrophil elastase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chediak-Higashi syndrome (OMIM #214500)",
"       </td>",
"       <td>",
"        Ulcerations of oral mucosa, severe gingivitis, glossitis, periodontal breakdown and bone loss",
"       </td>",
"       <td>",
"        Partial albinism, neutropenia, recurrent infections of skin and respiratory tract, frequently lethal before age seven years",
"       </td>",
"       <td>",
"        Autosomal recessive trait, deficiency of natural killer lymphocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Langerhans cell histiocytosis (histiocytosis X) (OMIM 604856)",
"       </td>",
"       <td>",
"        Ulcerative gingivitis, root exposure, and premature tooth mobility, typically starting with posterior teeth",
"       </td>",
"       <td>",
"        Bone lesions, multiorgan involvement, seborrheic scalp rash, diabetes insipidus, growth retardation",
"       </td>",
"       <td>",
"        Proliferation of Langerhans cell, (dendritic histiocytes), immunologic dysregulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prepubertal periodontitis (OMIM #170650)",
"       </td>",
"       <td>",
"        Variable gingival inflammation (localized minor to generalized severe), alveolar bone loss, typically starting with posterior teeth",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Autosomal dominant trait, leukocyte defect involving chemotaxis or phagocytosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:986. Copyright 2000 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23084=[""].join("\n");
var outline_f22_34_23084=null;
var title_f22_34_23085="HRT and CHD HERS II";
var content_f22_34_23085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Estrogen therapy not beneficial for secondary prevention of coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the HERS-II trial on the incidence of coronary heart disease events (death or nonfatal myocardial infarction) in 2763 postmenopausal women with a prior history of myocardial infarction or interventional procedure who were treated with combined hormone replacement therapy of placebo. There was no difference between the two groups. The curves are truncated at year 7 when less than half of the cohort remained in follow-up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Grady D, Herrington D, Bittner V, et al. JAMA 2002; 288:49.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23085=[""].join("\n");
var outline_f22_34_23085=null;
var title_f22_34_23086="Systolic diastolic dysfunction";
var content_f22_34_23086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Systolic versus diastolic dysfunction in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 190px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressure-volume loops in normal subjects (in blue) and those with heart failure due to systolic (left panel) or diastolic (right panel) dysfunction. The pressure-volume loop is shifted to the right with systolic dysfunction. The end-diastolic pressure is increased compared to normal (25 versus 10 mmHg in this example), but at a higher ventricular volume and lower ejection fraction. In contrast, the pressure-volume loop is shifted to the left with isolated diastolic dysfunction. Contractility is normal in this setting, but the increase in ventricular stiffness results in an elevated end-diastolic pressure at a lower left ventricular volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Zile, MR, Concepts Cardiovasc Dis 1990; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23086=[""].join("\n");
var outline_f22_34_23086=null;
var title_f22_34_23087="ALK fusion oncogenes and downstream signaling pathways";
var content_f22_34_23087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Schematic of ALK fusion oncogenes and important downstream signaling pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 407px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaw AT, Solomon B. Targeting Anaplastic Lymphoma Kinase in Lung Cancer. Clin Cancer Res 2011; 17: 2081. Copyright &copy; 2011 American Association for Cancer Research. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_34_23087=[""].join("\n");
var outline_f22_34_23087=null;
